

DCP3 Series Acknowledgments

Disease Control Priorities, third edition (DCP3) compiles the global health knowledge of institutions and experts from around the world, a task that required the efforts of over 500 individuals, including volume editors, chapter authors, peer reviewers, advisory committee members, and research and staff assistants. For each of these contributions we convey our acknowledgment and appreciation. First and foremost, we would like to thank our 32 volume editors who provided the intellectual vision for their volumes based on years of professional work in their respective fields, and then dedicated long hours to reviewing each chapter, providing leadership and guidance to authors, and framing and writing the summary chapters. We also thank our chapter authors who collectively volunteered their time and expertise to writing over 170 comprehensive, evidence-based chapters.

We owe immense gratitude to the institutional sponsor of this effort: The Bill & Melinda Gates Foundation. The Foundation provided sole financial support of the Disease Control Priorities Network. Many thanks to Program Officers Kathy Cahill, Philip Setel, Carol Medlin, Damian Walker, and (currently) David Wilson for their thoughtful interactions, guidance, and encouragement over the life of the project. We also wish to thank Jaime Sepúlveda for his longstanding support, including chairing the Advisory Committee for the second edition and, more recently, demonstrating his vision for DCP3 while he was a special advisor to the Gates Foundation. We are also grateful to the University of Washington’s Department of Global Health and successive chairs King Holmes and Judy Wasserheit for providing a home base for the DCP3 Secretariat, which included intellectual collaboration, logistical coordination, and administrative support.

We thank the many contractors and consultants who provided support to specific volumes in the form of economic analytical work, volume coordination, chapter drafting, and meeting organization: the Center for Disease Dynamics, Economics & Policy; Center for Chronic Disease Control; Centre for Global Health Research; Emory University; Evidence to Policy Initiative; Public Health Foundation of India; QURE Healthcare; University of California, San Francisco; University of Waterloo; University of Queensland; and the World Health Organization.

We are tremendously grateful for the wisdom and guidance provided by our advisory committee to the editors. Steered by Chair Anne Mills, the advisory committee ensures quality and intellectual rigor of the highest order for DCP3.

The National Academies of Science, Engineering, and Medicine, in collaboration with the Interacademy Medical Panel, coordinated the peer-review process for all DCP3 chapters. Patrick Kelley, Gillian Buckley, Megan Ginivan, Rachel Pittluck, and Tara Mainiero managed this effort and provided critical and substantive input.

World Bank Publications provided exceptional guidance and support throughout the demanding production and design process. We would particularly like to thank Carlos Rossel, Mary Fisk, Nancy Lammers, Rumit Pancholi, Deborah Naylor, and Sherrie Brown for their diligence and expertise. Additionally, we thank Jose de Buerba, Mario Trubiano, Yulia Ivanova, and Chiamaka Osuagwu of the World Bank for providing professional counsel on communications and marketing strategies.

Several U.S. and international institutions contributed to the organization and execution of meetings that
supported the preparation and dissemination of DCP3. We would like to express our appreciation to the following institutions:

- University of Bergen, consultation on equity (June 2011)
- University of California, San Francisco, surgery volume consultations (April 2012, October 2013, February 2014)
- Institute of Medicine, first meeting of the Advisory Committee to the Editors (March 2013)
- Harvard Global Health Institute, consultation on policy measures to reduce incidence of noncommunicable diseases (July 2013)
- National Academy of Medicine, systems strengthening meeting (September 2013)
- Center for Disease Dynamics, Economics & Policy (Quality and Uptake meeting, September 2013, reproductive and maternal health volume consultation, November 2013)
- National Cancer Institute cancer consultation (November 2013)
- Union for International Cancer Control cancer consultation (November 2013, December 2014)
- Harvard T. H. Chan School of Public Health, economic evaluation consultation (September 2015)
- University of California, Berkeley School of Public Health, and Stanford Medical School, occupational and environmental health consultations (December 2015).

Carol Levin provided outstanding governance for cost and cost-effectiveness analysis. Stéphane Verguet added valuable guidance in applying and improving the extended cost-effectiveness analysis method. Elizabeth Brouwer, Kristen Danforth, Nazila Dabestani, Shane Murphy, Zachary Olson, Jinyuan Qi, and David Watkins provided exceptional research assistance and analytic assistance. Brianne Adderley ably managed the budget and project processes, while Jennifer Nguyen, Shamelle Richards, and Jennifer Grasso contributed exceptional project coordination support. The efforts of these individuals were absolutely critical to producing this series, and we are thankful for their commitment.
Volume and Series Editors

VOLUME EDITORS

King K. Holmes

King K. Holmes is the Director of Research and Faculty Development in the University of Washington’s Department of Global Health. He also serves as Director of the Center for AIDS Research and Professor in the University of Washington’s Department of Medicine, and as Principal Investigator for the University of Washington’s International Training and Education Center for Health, with HIV-related programs in 20 countries throughout the world. He served as the William H. Foege Endowed Chair in Health from 2006 to 2015. Holmes has participated in research on sexually transmitted infections (STIs) for over 50 years and in research, training, and technical assistance on HIV/AIDS and other STIs globally for over 30 years.

Stefano Bertozzi

Stefano Bertozzi is Dean and Professor at the School of Public Health at the University of California, Berkeley. He has led impact evaluations of large, national health and social programs in Africa, Asia, Latin America, and Mexico. His research focuses on the prevention of HIV/AIDS and STIs, as well as on risk behavior among adolescents. He was previously the director of the HIV Global Health Program at the Bill & Melinda Gates Foundation. His research has covered a diverse range of projects in health economics and policy, focusing on the economic aspects of HIV/AIDS and the health impact of large social programs.

Barry R. Bloom

Barry R. Bloom is Harvard University Distinguished Service Professor of the Departments of Immunology and Infectious Diseases and Global Health and Population of the Harvard T. H. Chan School of Public Health, where he served as Dean from 1999 to 2009. His research interests have been in immunology, infectious diseases, tuberculosis, leprosy, and vaccines. He served as a consultant to the White House on international health policy and has been extensively involved with the World Health Organization, chairing advisory committees on tropical diseases, leprosy, tuberculosis, and malaria. He serves as Co-Chair of the Independent Expert Committee of the Human Heredity and Health in Africa (H3Africa) program; is a member of the Scientific Advisory Board of the Africa Health Research Institute in Durban, South Africa; and chairs the Research Advisory Committee of the Public Health Foundation of India.

Prabhat Jha

Prabhat Jha is the founding director of the Centre for Global Health Research at St. Michael’s Hospital. He holds Endowed and Canada Research Chairs in Global Health in the Dalla Lana School of Public Health at the University of Toronto. He is lead investigator of the Million Death Study in India, which quantifies the cause of death and key risk factors in over two million homes over a 14-year period. He is also Scientific Director of the Statistical Alliance for Vital Events, which aims to expand reliable measurement of causes of death worldwide. His research includes the epidemiology and economics of tobacco control worldwide.

SERIES EDITORS

Dean T. Jamison

Dean T. Jamison is Emeritus Professor in Global Health Sciences at the University of California, San Francisco,
and the University of Washington. He previously held academic appointments at Harvard University and the University of California, Los Angeles. Prior to his academic career, he was an economist on the staff of the World Bank, where he was lead author of the World Bank’s World Development Report 1993: Investing in Health. He serves as lead editor for DCP3 and was lead editor for the previous two editions. He holds a PhD in economics from Harvard University and is an elected member of the Institute of Medicine of the U.S. National Academy of Sciences. He recently served as Co-Chair and Study Director of The Lancet’s Commission on Investing in Health.

Rachel Nugent

Rachel Nugent is Vice President for Global Non-communicable Diseases at RTI International. She was formerly a Research Associate Professor and Principal Investigator of DCPN in the Department of Global Health at the University of Washington. Previously, she served as Deputy Director of Global Health at the Center for Global Development, Director of Health and Economics at the Population Reference Bureau, Program Director of Health and Economics Programs at the Fogarty International Center of the National Institutes of Health, and senior economist at the Food and Agriculture Organization of the United Nations. From 1991–97, she was associate professor and department chair in economics at Pacific Lutheran University.

Hellen Gelband

Hellen Gelband is an independent global health policy expert. Her work spans infectious disease, particularly malaria and antibiotic resistance, and noncommunicable disease policy, mainly in low- and middle-income countries. She has conducted policy studies at Resources for the Future, the Center for Disease Dynamics, Economics & Policy, the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the U.S. National Academies, and a number of international organizations.

Susan Horton

Susan Horton is Professor at the University of Waterloo and holds the Centre for International Governance Innovation (CIGI) Chair in Global Health Economics in the Balsillie School of International Affairs there. She has consulted for the World Bank, the Asian Development Bank, several United Nations agencies, and the International Development Research Centre, among others, in work conducted in over 20 low- and middle-income countries. She led the work on nutrition for the Copenhagen Consensus in 2008, when micronutrients were ranked as the top development priority. She has served as associate provost of graduate studies at the University of Waterloo, vice-president academic at Wilfrid Laurier University in Waterloo, and interim dean at the University of Toronto at Scarborough.

Prabhat Jha

See the list of Volume Editors.

Ramanan Laxminarayan

Ramanan Laxminarayan is Director of the Center for Disease Dynamics, Economics & Policy in Washington, DC. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He was one of the key architects of the Affordable Medicines Facility–malaria, a novel financing mechanism to improve access and delay resistance to antimalarial drugs. In 2012, he created the Immunization Technical Support Unit in India, which has been credited with improving immunization coverage in the country. He teaches at Princeton University.

Charles N. Mock

Charles N. Mock, MD, PhD, FACS, has training as both a trauma surgeon and an epidemiologist. He worked as a surgeon in Ghana for four years, including at a rural hospital (Berekum) and at the Kwame Nkrumah University of Science and Technology (Kumasi). In 2005–07, he served as Director of the University of Washington’s Harborview Injury Prevention and Research Center. He worked at the WHO headquarters in Geneva from 2007 to 2010, where he was responsible for developing the WHO’s trauma care activities. In 2010, he returned to his position as Professor of Surgery (with joint appointments as Professor of Epidemiology and Professor of Global Health) at the University of Washington. His main interests include the spectrum of injury control, especially as it pertains to low- and middle-income countries: surveillance, injury prevention, prehospital care, and hospital-based trauma care. He was President of the International Association for Trauma Surgery and Intensive Care from 2013–15.
Contributors

Elaine J. Abrams
Mailman School of Public Health, Columbia University, New York, New York, United States

Saeed Ahmed
Baylor College of Medicine–Abbott Fund Children’s Clinical Center of Excellence, Lilongwe, Malawi

Sevgi O. Aral
Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Rifat Atun
Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Joseph B. Babigumira
Department of Global Health, University of Washington, Seattle, Washington, United States

Sarah J. Baird
Milken Institute School of Public Health, The George Washington University, Washington, DC, United States

Till Bärnighausen
Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Fred Newton Binka
University of Health and Allied Sciences, Ho, Ghana

Lori A. Bollinger
Avenir Health, Glastonbury, Connecticut, United States

Donald A. P. Bundy
Bill & Melinda Gates Foundation, London, United Kingdom

Corey Casper
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Marcia Castro
Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Harrell W. Chesson
Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Justin Cohen
Clinton Health Access Initiative, Boston, Massachusetts, United States

Myron S. Cohen
University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States

Ted Cohen
Yale School of Public Health, New Haven, Connecticut, United States

Chris Cotter
University of California, San Francisco Medical Center, San Francisco, California, United States

Heidi Crane
Department of Global Health, University of Washington, Seattle, Washington, United States

John A. Crump
Department of Economics, University of Otago, Dunedin, New Zealand

Gina Dallabetta
Bill & Melinda Gates Foundation, Seattle, Washington, United States
Contributors

Kristen Danforth
Department of Global Health, University of Washington, Seattle, Washington, United States

Lisa M. DeMaria
Berkeley School of Public Health, Berkeley, California, United States

Sake J. de Vlas
Department of Public Health, University Medical Center Rotterdam, the Netherlands

Charlotte Dolenz
Clinton Health Access Initiative, Boston, Massachusetts, United States

Christopher Dye
Office of the Director-General, World Health Organization, Geneva, Switzerland

Wafaa M. El-Sadr
Mailman School of Public Health, Columbia University, New York, New York, United States

Joanne E. Enstone
School of Medicine, University of Nottingham, Nottingham, United Kingdom

Richard Feachem
Global Health Sciences, University of California, San Francisco, San Francisco, California, United States

Christopher Fitzpatrick
Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland

Hamish Fraser
Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States

Patricia J. Garcia
Ministry of Health, Lima, Peru

Geoffrey P. Garnett
Bill & Melinda Gates Foundation, Seattle, Washington, United States

Louis P. Garrison Jr.
Department of Global Health, University of Washington, Seattle, Washington, United States

Hellen Gelband
Disease Control Priorities Network, Washington, DC, United States

Gabriela B. Gomez
London School of Hygiene & Tropical Medicine, London, United Kingdom

Roland Gosling
Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, California, United States

Reuben Granich
International Association of Providers of AIDS Care, Washington, DC, United States

Simon A. J. Gregson
Biomedical Research and Training Institute, Harare, Zimbabwe

Timothy B. Hallett
School of Public Health, Imperial College London, London, United Kingdom

James R. Hargreaves
London School of Hygiene & Tropical Medicine, London, United Kingdom

Katherine Harripersaud
Mailman School of Public Health, Columbia University, New York, New York, United States

Kate L. Harris
Bill & Melinda Gates Foundation, Seattle, Washington, United States

Bernadette Hensen
London School of Hygiene & Tropical Medicine, London, United Kingdom

Charles B. Holmes
Centre for Infectious Disease Research, Lusaka, Zambia

Susan Horton
School of Public Health and Health Systems, University of Waterloo, Waterloo, Canada

Grace John-Stewart
Department of Global Health, University of Washington, Seattle, Washington, United States

James G. Kahn
Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, California, United States

John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya

Gwen Knight
London School of Hygiene & Tropical Medicine, London, United Kingdom

Shari Krishnaratne
London School of Hygiene & Tropical Medicine, London, United Kingdom
Advisory Committee to the Editors

Anne Mills, Chair
Professor, London School of Hygiene & Tropical Medicine, London, United Kingdom

Olusoji Adeyi
Director, Health, Nutrition and Population Global Practice, World Bank, Washington, DC, United States

Kesetebirhan Admasu
Minister of Health, Addis Ababa, Ethiopia

George Alleyne
Director Emeritus, Pan American Health Organization, Washington, DC, United States

Ala Alwan
Regional Director Emeritus, World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Arab Republic of Egypt

Rifat Atun
Professor, Global Health Systems, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Zulfiqar Bhutta
Chair, Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

Agnes Binagwaho
Former Minister of Health, Kigali, Rwanda

Mark Blecher
Senior Health Advisor, South Africa Treasury Department, Cape Town, South Africa

Patricia Garcia
Minister of Health, Lima, Peru

Roger Glass
Director, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States

Amanda Glassman
Chief Operating Officer and Senior Fellow, Center for Global Development, Washington, DC, United States

Glenda Gray
Executive Director, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Demissie Habte
Chair of Board of Trustees, International Clinical Epidemiological Network, Addis Ababa, Ethiopia

Richard Horton
Editor, The Lancet, London, United Kingdom

Edward Kirumira
Dean, Faculty of Social Sciences, Makerere University, Kampala, Uganda

Peter Lachmann
Professor, University of Cambridge, Cambridge, United Kingdom

Lai Meng Looi
Professor, University of Malaya, Kuala Lumpur, Malaysia

Adel Mahmoud
Senior Molecular Biologist, Princeton University, Princeton, New Jersey, United States

Anthony Measham
World Bank (retired)
Carol Medlin
Independent Consultant, Washington, DC, United States

Alvaro Moncayo
Researcher, Universidad de los Andes, Bogotá, Colombia

Jaime Montoya
Executive Director, Philippine Council for Health Research and Development, Taguig City, the Philippines

Ole Norheim
Professor, Department of Global Health and Primary Care, University of Bergen, Bergen, Norway

Folashade Omokhodion
Professor, University College Hospital, Ibadan, Nigeria

Toby Ord
President, Giving What We Can, Oxford, United Kingdom

K. Srinath Reddy
President, Public Health Foundation of India, New Delhi, India

Sevket Ruacan
Dean, Koç University School of Medicine, Istanbul, Turkey

Jaime Sepúlveda
Executive Director, Global Health Sciences, University of California, San Francisco, California, United States

Richard Skolnik
Yale University School of Public Health (retired)

Stephen Tollman
Professor, University of Witwatersrand, Johannesburg, South Africa

Jürgen Unutzer
Professor, Department of Psychiatry, University of Washington, Seattle, Washington, United States

Damian Walker
Deputy Director of Data and Analytics, Bill & Melinda Gates Foundation, Seattle, Washington, United States

Ngaire Woods
Director, Global Economic Governance Program, Oxford University, Oxford, United Kingdom

Nopadol Wora-Urai
Professor, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand

Kun Zhao
Researcher, China National Health Development Research Center, Beijing, China
Ramanan Laxminarayan  
Center for Disease Dynamics, Economics & Policy,  
Washington, DC, United States

Christian Lengeler  
Swiss Tropical and Public Health Institute, Basel,  
Switzerland

Edeltraud Lenk  
Erasmus University Rotterdam, Rotterdam, the  
Netherlands

Carol Levin  
Department of Global Health, University of  
Washington, Seattle, Washington, United States

Jenny Liu  
Global Health Sciences, University of California, San  
Francisco, San Francisco, California, United States

Yoel Lubell  
Mahidol Oxford Tropical Medicine Research Unit,  
Bangkok, Thailand

David Mabey  
London School of Hygiene & Tropical Medicine,  
London, United Kingdom

Kudzai Makomva  
Malaria Elimination 8 Secretariat, Windhoek, Namibia

Elliot Marseille  
Health Strategies International, San Francisco,  
California, United States

Philippe Mayaud  
London School of Hygiene & Tropical Medicine,  
London, United Kingdom

Margaret McNairy  
Weill Cornell Medical College, Cornell University,  
Ithaca, New York, United States

Didier Ménard  
Worldwide Antimalarial Resistance Network,  
Paris, France

Molly Miller-Petrie  
Center for Disease Dynamics, Economics & Policy,  
Washington, DC, United States

Deborah Money  
Department of Obstetrics & Gynecology, University  
of British Columbia, Vancouver, British Columbia,  
Canada

Meghan Murray  
Harvard T.H. Chan School of Public Health, Boston,  
Massachusetts, United States

Edward Nardell  
Harvard T. H. Chan School of Public Health, Boston,  
Massachusetts, United States

Gretchen Newby  
Global Health Sciences, University of California,  
San Francisco, San Francisco, California,  
United States

Paul N. Newton  
Lao-Oxford-Mahosot Hospital, Wellcome Trust  
Research Unit, Vientiane, the Lao People’s Democratic  
Republic

Uzoma Nwankwo  
Federal Ministry of Health of Nigeria, Abuja, Nigeria

Nancy Padian  
Berkeley School of Public Health, University of  
California, Berkeley, California, United States

Rosanna W. Peeling  
International Diagnostics Centre, London School  
of Hygiene & Tropical Medicine, London,  
United Kingdom

Allison Phillips  
Global Health Sciences, University of California, San  
Francisco, San Francisco, California, United States

Yogan Pillay  
South African National Department of Health, Pretoria,  
South Africa

Suraj Pant  
Center for Disease Dynamics, Economics & Policy,  
Washington, DC, United States

Paul Revill  
Centre for Health Economics, University of York, York,  
United Kingdom

Eric Rubin  
Harvard T. H. Chan School of Public Health, Boston,  
Massachusetts, United States

Joshua Salomon  
Harvard T. H. Chan School of Public Health, Boston,  
Massachusetts, United States

Michael Santos  
Bill & Melinda Gates Foundation, Seattle, Washington,  
United States

Rima Shretta  
Global Health Sciences, University of California, San  
Francisco, San Francisco, California, United States
John Stover
Avenir Health, Glastonbury, Connecticut, United States

Jessica Taaffe
World Bank, Washington, DC, United States

Marcel Tanner
Swiss Tropical and Public Health Institute, Basel, Switzerland

Allison Tatarsky
Clinton Health Access Initiative, Boston, Massachusetts, United States

Fabrizio Tediosi
Swiss Tropical and Public Health Institute, Basel, Switzerland

Harsha Thirumurthy
Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, United States

Anna Vassal
London School of Hygiene & Tropical Medicine, London, United Kingdom

Grigory Volchenkov
Vladimir Oblast Tuberculosis Dispensary, Center of Excellence for Tuberculosis Infection Control, Vladimir, the Russian Federation

Rochelle P. Walensky
Harvard Medical School, Boston, Massachusetts, United States

Tim Wells
Medicines for Malaria Venture, Geneva, Switzerland

Richard White
London School of Hygiene & Tropical Medicine, London, United Kingdom

Danielle Wideman
Berkeley School of Public Health, University of California, Berkeley, California, United States

Stefan Z. Wiktor
Department of Global Health, University of Washington, Seattle, Washington, United States

David Wilson
World Bank, Washington, DC, United States

Douglas Wilson
Department of Medicine, Edendale Hospital, KwaZulu-Natal, South Africa

Prashant Yadav
William Davidson Institute, University of Michigan, Ann Arbor, Michigan, United States
Reviewers

Leela Barham
Economic Consulting LTD, Royston, United Kingdom

Zulfqar A. Bhutta
Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

Richard E. Chaisson
Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States

Arantxa Colchero
Center for Health Systems Research, National Institute of Public Health, Cuernavaca, Mexico

James Curran
Rollins School of Public Health, Emory University, Atlanta, Georgia, United States

Helen Fletcher
Tuberculosis Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom

Omar Galárraga
Brown University School of Public Health, Providence, Rhode Island, United States

Glenda Gray
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Laura A. Guay
Milken Institute School of Public Health, George Washington University, Washington, DC, United States

Kristian Schultz Hansen
Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, United Kingdom

Cecilia T. Hugo
ACTMalaria, Manila, the Philippines

Salim S. Abdool Karim
Centre for the AIDS Programme of Research in South Africa (CAPRISA), Columbia University, Durban, South Africa

Michael Lynch
Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Kamini Mendis
Independent Consultant, Colombo, Sri Lanka

Praphan Phanuphak
Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Anthony Seddoh
Health, Nutrition and Population Global Practice, World Bank, Accra, Ghana

Laurence Slutsker
Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Samuel So
Asian Liver Center, Stanford University School of Medicine, Palo Alto, California, United States
Sunil Suhas Solomon  
Johns Hopkins University School of Medicine,  
Baltimore, Maryland, United States

Neeraj Sood  
Sol Price School of Public Policy and Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, United States

Paul Volberding  
AIDS Research Institute, University of California, San Francisco, San Francisco, California, United States

Diana Weil  
Global TB Programme, World Health Organization,  
Geneva, Switzerland

Mary E. Wilson  
Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States
Index

Boxes, figures, maps, notes, and tables are indicated by b, f, m, n, and t following the page number.

A
Abrams, Elaine J., 67
Abu-Raddad, L. J., 283
Acinetobacter spp., 366
ADCs (AIDS-defining cancers), 45, 46

adherence to treatment
HIV/AIDS, 79–81
barriers, 79–80
cost-effectiveness, 81
decentralized care and, 81
guidelines, 79
improvement approaches, 80–81
measurement of, 79
mother-to-child transmission (MTCT), 122
peer counseling and, 81
rationale and coverage, 79
tuberculosis, 274–75
adolescents. See also children
febrile illness among, 365–84
burden of, 365–66
cost-effectiveness of interventions, 374–79, 376–77f
costs of, 373, 374f
diagnosis, 369, 370–71t, 372–73, 378
at district hospital facilities, 371–72
etiology of, 366
at first-level health facilities, 371
future research needs, 377–79
incidence rates, 366–68, 368–69r
sepsis management and, 375
surveillance, 375
treatment interventions, 370–71t, 371–72
HIV/AIDS among, 8, 38
adherence to treatment, 80
testing services, 68, 69
AEM. See AIDS Epidemic Model
Afghanistan, cutaneous leishmaniasis in, 422
Africa. See also specific countries and regions
febrile illness in, 366
hepatitis in, 404
malaria control in, 348
tuberculosis incidence rates, 240
Africa Centre, 104b
African Americans
dyslipidemia among, 55
as HIV/AIDS key population, 36–37
African Leaders Malaria Alliance, 316
Agence Nationale de Recherche, 104b
agricultural usage of antibiotics, 438, 439f, 441–42, 442t
Ahmed, Saeed, 67
AIDS-defining cancers (ADCs), 45, 46
AIDS Epidemic Model (AEM), 180, 181–85t, 186, 192, 196–97
AIDS Impact Model (AIM), 186, 187
Alam, N., 214
Alistar, S. S., 97
Ambinder, R. F., 47
amikacin, 252, 253
anal cancer, 45
anal sex, 207
Anderson, S., 35, 36
Angola, malaria elimination in, 321b
antibiotics and antimicrobial resistance, 19–20, 433–48
drivers of use, 19, 435–39, 437m
food animal production usage, 438, 439f, 441–42, 442f
health care usage, 435–38
hospital usage, 438, 438f, 441
interventions to ensure appropriate use, 19–20, 439–43
agricultural usage regulations, 438, 439f, 441–42, 442f
education and awareness campaigns, 441–42
in hospitals, 441
incentives, 441
surveillance, 442–43
vaccinations, 440–41
water, sanitation, and hygiene, 439–40
sexually transmitted infections and, 208
antiretroviral treatment (ART), 5
cardiocvascular disease and, 53
effectiveness of, 91
mortality rates and, 208
mother-to-child transmission (MTCT) and, 91, 121, 122
for persons who inject drugs (PWIDs), 163
preexposure prophylaxis (PrEP) and, 93
resource allocation modeling and, 197, 198
transmission biology and, 92
tuberculosis treatment and, 253–54
Arab Republic of Egypt. See Egypt, Arab Republic of
Aral, Sevgi O., 203, 222, 223
Argentina, malaria elimination in, 315
Armenia, malaria elimination in, 315
ART. See antiretroviral treatment
artemisinin-based combination therapies (ACTs), 318, 327–28, 385
artemisinin resistance, 322–24, 323m
ascariasis, 416
Asia Pacific Leaders Malaria Alliance, 316
Attia, S., 93
Atun, Rifat, 233, 235
Australia
hepatitis in, 407
HIV/AIDS in
localized intervention programs, 163
men who have sex with men (MSM), 163
treatment as prevention (TasP), 94
sexually transmitted infections in, 214
tuberculosis interventions in, 280
autopsy procedures, 366
Avahan Program, 148, 163, 216
Avenir Health models, 146, 180, 181–85t, 186–90
Azerbaijan, malaria elimination in, 315, 321b
azithromycin, 216, 420, 421, 422
B
Babigumira, Joseph B., 385
bacille Calmette–Guérin (BCG) vaccine, 233, 243, 255–56, 278, 279
bacterial sepsis, 375
bacterial vaginosis, 46, 52, 145
Baggaley, R. F., 222
Baird, Sarah J., 365, 375
Bangladesh
resource allocation modeling in, 197
sexually transmitted infections in, 214, 215
tuberculosis in
community-based care, 266
diagnosis, 263b
hospital-based care in, 264
information management system, 275
research and development, 283
typhoid in, 373
vector control interventions in, 419
visceral leishmaniasis in, 19, 415
Bärnighausen, T., 97
Baxi, Sanjiv, 29
Baxter, C., 214
BCG. See bacille Calmette–Guérin vaccine
bedaquiline, 251, 253, 277, 284
behavioral change
HIV/AIDS, 49
sexually transmitted infections and, 8, 207, 210, 219
behavioral economics, 198–99
Belarus, HIV/AIDS in, 171, 171f
Bendavid, E., 97
Benin
HIV/AIDS testing services in, 70
sexually transmitted infections in, 216
Bertozzi, Stefano, 1
Bill & Melinda Gates Foundation, 148, 163, 187, 198, 280, 348, 349
Bingham, A. L., 223
bisexual persons. See lesbian, gay, bisexual, and transgender (LGBT) persons
Blacksell, S. D., 367
Blaya, J. A., 273
blood supply safety, 16, 405
Bloom, Barry R., 11, 233
Bloom, D. E., 97
Blower, S., 95
Bollinger, Lori A., 148, 179, 188
Borghi, J., 221
Botswana
HIV/AIDS in
cardiovascular disease comorbidity, 53
morbidity rates, 33
mother-to-child transmission, 125
treatment as prevention (TasP), 104b
malaria elimination in, 321b
Boyd, M. F., 337
Brandeau, M. L., 97
Brazil
antibiotic use in, 438
febrile illness in, 386
hepatitis treatment access in, 405
HIV/AIDS in
dyslipidemia comorbidity, 56
incidence rates, 35
syphilis in, 130
tuberculosis in
diagnosis, 263
pharmaceutical supply chain, 272
preventive therapy, 257
research and development, 283
brucellosis, 367, 368
Brunei Darussalam, malaria in, 318
Bundy, Donald A. P., 411
burden of disease
antiretroviral treatment (ART) and, 208
Burkholderia pseudomallei, 373
cardiomyopathy, 52–53
chlamydia, 7, 207
by country income group, 2, 2t
dengue, 413, 413t, 414–15
diabetes mellitus, 54
dyslipidemia, 55
febrile illness, 365–66, 397, 397t
gonorrhea, 7, 207
hepatitis, 16, 402, 403f, 403m
herpes simplex virus (HSV-1 and HSV-2), 207
HIV/AIDS, 31–33, 31–33f, 31f, 32–33
comorbidities, 45–66
mother-to-child transmission (MTCT), 114–19, 114t, 116–19m
human African trypanosomiasis (HAT), 416
human papillomavirus (HPV), 7, 207
leptospirosis, 373
malaria, 316, 348, 373, 413, 413r
meliodosis, 373
neglected tropical diseases (NTDs), 19, 412–15, 413–14t, 414f
Orientia tsutsugamushi, 373
schistosomiasis, 416
sexually transmitted infections, 7–8, 204–7
syphilis, 7, 114–19, 114t, 116–19m, 207
trichomoniasis, 7, 207
tuberculosis, 234, 237–42, 238–39t, 244
typhoid, 373
visceral leishmaniasis, 416
WHO estimates on, 380n1
Burkholderia pseudomallei, 373
Burkina Faso, HIV/AIDS in, 159
Burnet Institute, 180
Buruli ulcer, 18, 414, 419
C
CAESAR (Central Asian and Eastern European Surveillance of Antimicrobial Resistance), 443
Cambodia
dengue in, 414–15
febrile illness in, 367
malaria in
incidence rates, 316
interventions, 321b
sexually transmitted infections in, 221
tuberculosis diagnosis in, 262
Cameroon
Buruli ulcer in, 414
HIV/AIDS in
dyslipidemia comorbidity, 55, 56
testing services, 70
sexually transmitted infections in, 215
Canada
antimicrobial resistance in, 440
HIV/AIDS in, 95
malaria elimination in, 326
sexually transmitted infections in, 203, 214
tuberculosis in, 280
cancer
HIV/AIDS comorbidity, 46–50
anal cancer, 48
behavioral interventions, 49
cervical cancer, 47
chemoprevention of, 49
epidemiology of, 46–47
hepatocellular carcinoma (HCC), 48
Kaposi sarcoma (KS), 47
lung cancer, 48
lymphoma, 47–48
pathogenesis of HIV-associated malignancies, 47
prevention strategies, 48–49
screening for, 49
vaccines and, 48–49
Canchihuaman, F. A., 9
Candida spp., 367
carbamazepine, 253
cardiovascular disease and HIV/AIDS comorbidity, 52–54
  ART impact on, 53
  burden of, 52–53
  epidemiology of, 52–53
  factors associated with, 53
Caribbean. See Latin America and Caribbean
Carrara, V., 221
Casper, Corey, 45, 47
Castellsague, X., 210
Castro, Marcia, 347
Cates, W., 144
CBT (community-based testing), 69
Celli, Angelo, 352
Center for Disease Dynamics, 439
Centers for Disease Control and Prevention (CDC), 24n1, 30, 75, 433
Central African Republic, syphilis in, 203
Central Asian and Eastern European Surveillance of Antimicrobial Resistance (CAESAR), 443
cephalosporins, 208
cervical cancer
  HIV/AIDS comorbidity, 45, 46, 47
  HPV and, 205
  incidence rates, 7
  screening for, 49
Chagas disease
  cost-effectiveness of interventions, 421
  interventions for, 18, 414
  mortality and morbidity rates, 413, 413t, 416
  vector control interventions, 418–19, 424, 427
  vector transmission prevention, 421
Chambers, R., 334
Charania, M. R., 217
Chersich, M., 215
Chesson, Harrell W., 203, 223
chikungunya, 366, 367, 419, 421
children. See also mother-to-child transmission (MTCT)
febrile illness among, 385–400
  costs of treatment, 394, 395–96t
  decision-analytic model for, 388–90, 388–89f
  diagnosis, 394, 395–96t
  mortality rates, 397, 397t
  study methodology, 386–94, 387t, 391–94t
hepatitis vaccinations for, 404, 406
HIV/AIDS among
  adherence to treatment, 79, 80
  linkage to care and treatment, 75, 76
  retention in care, 78
  testing services, 68, 69
  malaria among, 322, 348
  sexually transmitted infections among, 205
tuberculosis among
  comorbidities, 245
  vaccinations, 255–56
China
  antibiotic resistance in, 433, 434f, 441, 442
  antibiotic use in, 438
  febrile illness in, 367
  hepatitis in
    cost-effectiveness of interventions, 407
    vaccinations, 404, 406
HIV/AIDS in
  burden of, 116
  mother-to-child transmission, 130
  testing services, 70
  treatment as prevention (TasP), 93, 164
  malaria elimination in, 321b, 328–29
  malaria incidence rates in, 318
  syphilis in, 129, 130
  tuberculosis in
    diagnosis, 250
    incidence rates, 240
    pharmaceutical supply chain, 272
    treatment interventions, 254
chlamydia
  burden of, 7, 207
  incidence rates, 203
  male circumcision and, 210
Chlamydia trachomatis, 418
chloroquine (CQ), 350, 385
cholesterol, 55
CHWs (community health workers), 76
circumcision. See voluntary male medical circumcision (VMMC)
clofazamine, 253
Clostridium difficile, 433, 437, 440
Cochrane Library, 193, 210
Cohen, Justin, 315
Cohen, Ted, 233
Coker, R., 235
Colombia
  Chagas disease in, 421
  sexually transmitted infections in, 219
Commission on AIDS in Asia, 197
Commission on Macroeconomics and Health, 199
community-based interventions
HIV/AIDS, 163
  mother-to-child transmission (MTCT), 124
  testing services, 70, 75
  sexually transmitted infections, 216–17, 221–22
  tuberculosis, 264–69, 266f, 267t
  efficiency and effectiveness of, 265–66, 267t
  human resource challenges to, 267
  private sector challenges, 267–68
recommendations, 292
targeting, 268–69
community-based testing (CBT), 69
community health workers (CHWs), 76
comorbidities
HIV/AIDS, 45–66
  bacterial vaginosis, 52
cancer, 46–50
  cardiovascular disease, 52–54
diabetes mellitus, 54–55
dyslipidemia, 55–57
febrile illness, 368, 368r, 372
female reproductive health, 50–51
hepatitis C, 198
herpes simplex virus, 51
human papillomavirus (HPV), 51
malaria, 348
noncommunicable chronic comorbidities (NCCs), 52–57
other sexually transmitted infections, 51–52, 115
pelvic inflammatory disease, 51–52
sexually transmitted intestinal and enteric infections, 52
tuberculosis, 234, 239, 245
infection control and, 3
concentrated HIV/AIDS epidemics, 158, 159–60, 159–60f
condom use
HIV/AIDS and, 50, 137, 143–44, 161, 163
resource allocation modeling and, 198
sexually transmitted infection prevention via, 210
Copenhagen Consensus Center, 280
cost. See also cost-effectiveness of interventions
  of febrile illness, 373, 374f, 394, 395–96t
  of hepatitis, 406–7, 406t
  of HIV/AIDS
    prevention interventions, 146–50, 148r, 149–50f
    retention in care, 78–79
  of malaria control interventions, 350–51
  of neglected tropical diseases (NTDs) treatment interventions, 420–22, 420t
Costa Rica, malaria elimination in, 315
cost-effectiveness of interventions
dengue, 421
febrile illness, 374–77, 376–77f, 378–79
hepatitis, 406–7, 406t
HIV/AIDS, 76–77, 81
  local epidemics, 170–73, 171–73f, 172t
  mother-to-child transmission (MTCT), 125–29, 126–27r, 126f
  prevention, 137–56
  retention in care, 78–79
  testing services, 70–75, 71–74t
human African trypanosomiasis (HAT), 422
malaria control, 350–51
neglected tropical diseases (NTDs) treatment interventions, 420–22, 420t
point-of-care tests (POCTs), 378
preexposure prophylaxis (PrEP), 137, 149
sexually transmitted infection interventions, 217–22, 218–19t
syphilis, mother-to-child transmission (MTCT), 125–29, 126f, 128–29t
treatment as prevention (TasP), 96–102, 98–99t
  treatment interventions, 20–22, 21f
tuberculosis, 281–89, 285–86r, 288f
vaccines and vaccinations, 20
visceral leishmaniasis, 374, 422
yaws, 422
Côte d’Ivoire
  HIV/AIDS in, 78–79
  malaria elimination in, 334
  soil-transmitted helminthiases in, 421
  syphilis in, 203
  tuberculosis in, 257
cotrimoxazole, 254
Copier, Chris, 315
Crane, Heidi, 45
Crump, John A., 365, 366, 375
Cryptococcus spp., 367
Cuba, HIV/AIDS in, 114, 125
cutaneous leishmaniasis, 18, 421–22
cysticercosis, 2
D
DAA. See direct acting antiviral medicines
Dallabetta, Gina, 137
DALYs
  febrile illness, 366, 376, 378, 386
  HIV/AIDS, 33–34
  prevention interventions, 149, 151
  treatment as prevention (TasP), 96
  malaria, 351
  neglected tropical diseases and, 413, 421, 423, 425, 427
  resource allocation modeling and, 180, 199
  sexually transmitted infections and, 8, 205, 208, 221
  syphilis and, 129
  tuberculosis, 284
Danforth, Kristen, 29
Database of Abstracts of Reviews of Effects, 210
Davis, K. R., 144
Decision Makers’ Program Planning Tool (DMPPT)
  model, 189–90, 196
Deen, J., 367
delamanid, 251, 253, 277
DeMaria, Lisa M., 1
Democratic Republic of Congo
  antibiotic resistance in, 433, 434f
  human African trypanosomiasis in, 415, 422
  malaria control in, 348, 359
  malaria mortality rates in, 316
  tuberculosis in, 264
Demographic and Health Surveys, 39
DemProj, 186
dengue
  burden of, 414–15
  community-based care, 376
  cost-effectiveness of interventions, 421
  diagnosis, 372
  incidence rates, 365, 367, 368
  mortality and morbidity rates, 413, 413f
  vector control interventions, 419, 424, 427
  vector transmission prevention, 421
de Vlas, Sake J., 215, 411
diabetes mellitus
  febrile illness comorbidity, 368, 368f
  HIV/AIDS comorbidity, 54–55
    burden of, 54
    epidemiology of, 54
    factors associated with, 54–55
    as tuberculosis risk factor, 246–47
diagnosis
dengue, 372
  febrile illness, 369, 370–71f, 372–73, 378, 394, 395–96f
  malaria, 327–29, 350
  sexually transmitted infections, 206
  tuberculosis, 248–50, 249b, 261–64, 263b, 292
  typhoid, 369
diarrhea, 366, 378
digbeu, N., 214
diphtheria, 22
direct acting antiviral (DAA) medicines, 401, 405, 407
Djibouti, malaria in, 316
Dolenz, Charlotte, 315
Dominican Republic
  HIV/AIDS in, 160
  malaria elimination in, 331
  sexually transmitted infections in community-based interventions, 221
  structural interventions, 217
  DOTS strategy, 234, 240–41, 240b, 254, 291–92
Dowdy, D. W., 283
doxycycline, 375, 376
dracunculiasis (Guinea worm), 415
drug interventions. See also antibiotics and antimicrobial resistance; vaccines and vaccinations; specific medications
malaria, 353–56, 354–55f
  long-term chemoprotection via, 355–56
  transmission-blocking medicines, 355
mass drug administration (MDA), 327–28
neglected tropical diseases (NTDs), 18, 416–18, 420, 420f
sexually transmitted infections, 9
treatment as prevention (TasP), 103–4
tuberculosis
  drug toxicities and interactions, 253
  research and development, 275–80
Dua, V., 333
Dye, Christopher, 233, 241
dyslipidemia, 55–57, 55f
  as tuberculosis risk factor, 246–47
East Africa, HIV/AIDS in. See also specific countries
  comorbidities in, 47
  incidence rates in, 33, 35
  testing services in, 70
East Asia and Pacific. See also specific countries
  hepatitis in
    incidence rates, 16
    mortality rates, 401
  HIV/AIDS in
    comorbidities, 46
    concentrated epidemics, 159
    incidence rates, 33
    key populations, 37
    malaria elimination in, 332
Eastern Europe and Central Asia. See also specific countries
  antibiotic use in, 443
  hepatitis in
    incidence rates, 16
    prevalence, 401
  HIV/AIDS in
    allocative efficiency for interventions, 173, 173f
    incidence rates, 33
    key populations, 36
    morbidity rates, 33
East-West Center, 180
Eaton, J. W., 95–96, 97, 101
Ebola, 2, 8, 22, 206, 287
eChasqui, 273
ectopic pregnancies, 51
efavirenz, 253
Egypt, Arab Republic of
  hepatitis in
    incidence rates, 16
    prevalence, 401–2
  malaria elimination in, 315
electronic medical records (EMRs), 273–74
El-Sadr, Wafaa M., 67
El Salvador, syphilis in, 203
Embass, 210
End TB Strategy, 235, 291
Enstone, Joanne E., 137
enteritis, 52
enzyme-linked immunosorbent assay (ELISA) test, 119, 131n5
Epidemiological Modeling (EMOD), 180, 181–85, 186, 192
Epstein-Barr virus, 47
Eritrea
HIV/AIDS morbidity rates in, 33
Tuberculosis incidence rates in, 240
Escherichia coli, 366, 435, 436b, 440
Estonia
Tuberculosis diagnosis in, 249
Tuberculosis treatment in, 264
Ethambutol, 251, 253
Ethiopia
Antimicrobial resistance in, 439
HIV/AIDS in dyslipidemia comorbidity, 56
morbidity rates, 33
Trichiasis in, 413–14
Tuberculosis treatment in, 264
European Medicines Agency, 329, 356

F
Family Health International, 187
Family planning, 124
FamPlan model, 186
Feachem, Richard, 315
Febrile illness, 365–400
in adolescents and adults, 365–84
burden of, 365–66
Cost-effectiveness of interventions, 374–79, 376–77f
Costs of, 373, 374f
diagnosis, 369, 370–71t, 372–73, 378
at district hospital facilities, 371–72
etiology of, 366
at first-level health facilities, 371
future research needs, 377–79
Incidence rates, 366–68, 368–69f
Sepsis management and, 375
surveillance, 375
Treatment interventions, 370–71t, 371–72
in children, 385–400
Costs of treatment, 394, 395–96t
decision-analytic model for, 388–90, 388–89f
diagnosis, 394, 395–96t
mortality rates, 397, 397t
study methodology, 386–94, 387t, 391–94r
HIV/AIDS comorbidity, 368, 368t, 372
intervention packages, 14, 14–15t, 370–71t, 371–72
Federal Drug Administration (FDA, U.S.), 276
financing
in health system framework, 235f, 236
malaria elimination and eradication, 330–36, 331t, 333–35f, 335–36b
tuberculosis intervention programs, 280–81, 280–81f, 289–90, 290r
Fitzpatrick, Christopher, 411
Fluoroquinolone, 276
Fofana, O., 283
Fontanet, A. L., 210
Food animal production, antibiotic usage in, 438, 439f, 441–42, 442r
France, tuberculosis intervention financing in, 280
Fraser, Hamish, 233
Fraser, N., 95
Frenk, J., 235
Furness, B. W., 208
Futures Institute, 186

G
Galárraga, O., 146
Galeo, S., 289
Gallup, J. L., 333
Gandhi, N. R., 259
Gantt, S., 47
Garcia, Patricia J., 113
Garnett, Geoff P., 137
Garrison, Louis P., Jr., 385
Gates, B., 334
Gavi, the Vaccine Alliance, 24n10, 190, 220
gay persons. See lesbian, gay, bisexual, and transgender (LGBT) persons
GBD. See Global Burden of Disease
Gelband, Hellen, 1, 385
generalized HIV/AIDS epidemics, 158, 160–61
GeneXpert, 272, 282
Geng, E. H., 39
Geographic targeting, 167–70, 168–70m, 169f
Georgia, malaria elimination in, 315
Germany, tuberculosis intervention financing in, 280
Ghana
Buruli ulcer in, 414
Febrile illness in, 386
HIV/AIDS in concentrated epidemics, 160
men who have sex with men (MSM), 160
malaria elimination in, 12, 333
Sexually transmitted infections in, 216
GHD. See Global Health Decisions model
Glaxo-Smith-Kline, 104, 356
Global Action Plan on Antimicrobial Resistance, 439
Global Antibiotic Resistance Partnership, 443
Global Burden of Disease (GBD), 8, 33, 425. See also
burden of disease
Global Drug Facility, 270
Global Fund to Fight AIDS, Tuberculosis, and Malaria
on HIV/AIDS interventions, 20, 138, 190, 196
on malaria interventions, 318, 335, 349
on tuberculosis interventions, 240, 280
Global Health Cost Consortium, 198
Global Health Decisions (GHD) model, 180, 181–85t,
186, 192–93
Global Health Estimates database, 380n1
Global Health Observatory Data Repository, 203
Global Health Workforce Alliance, 190
Global Laboratory Initiative, 240
Global Malaria Action Plan (GMAP), 348, 349, 350
Global Malaria Eradication Program (GMEP), 318,
320, 330–31
Global Plan to Stop TB, 241, 258
Global Resource Needs Estimate (GRNE) model,
187, 196
glucocorticoids, 253
Goals model, 180, 181–85t, 188–89, 189f
Golden, M. R., 215
Goldie, S. J., 220
Goldmann, E., 289
Gomez, Gabriela B., 114–15, 233
gonococcal antimicrobial resistance, 208
gonorrhea
antimicrobial resistance and, 208
burden of, 7, 207
incidence rates, 203
income inequality and, 223
Gosling, Roly, 315
governance in health system framework, 235f, 236
Grading of Recommendations Assessment,
Development, and Evaluation (GRADE),
103, 121
Granich, Reuben, 29, 95, 97, 104
Grant, P. M., 97
Greece, malaria elimination in, 331
Green Light Committee, 240, 270
Gregson, Simon A. J., 137
Grossman, M., 217
Guinea, tuberculosis in, 287
Guinea worm infections, 2, 19, 337
H
HAIs. See health care-associated infections
Haiti
HIV/AIDS in, 130
HIV/AIDS in, 129, 130
tuberculosis in
community-based care, 266
information management system, 274
Hallett, Timothy B., 95–96, 137
Hargreaves, James R., 137
Harripersaud, Katherine, 67
Harris, Kate L., 137
HAT. See human African trypanosomiasis
HCC (hepatocellular carcinoma), 45
HDL (high-density lipoprotein) cholesterol, 55
Health Action, 394
health care-associated infections (HAIs), 434, 438, 441
Health Metrics Network, 190
Heimbeck, J., 256
Heller, P. S., 235
helminthiases, 416, 421
Henley, C., 215
Hensen, Bernadette, 137
hepatitis, 14–16, 401–10. See also specific strains below
diabetes mellitus comorbidity, 54
HIV/AIDS comorbidities, 48
incidence rates, 401–2, 402f, 402t
interventions, 16, 17t, 402t, 404–5
access to, 405, 407
blood supply safety, 16, 405
costs and cost-effectiveness, 406–7, 406t
harm reduction programs, 405
health care injection safety, 16, 405, 407
sanitation, 16, 404
vaccination, 16, 49, 404–5, 404f, 406
mortality rates, 16, 402, 403f, 403m
transmission of, 403–4
hepatitis A
incidence rates, 401
sanitation improvement interventions, 404
transmission of, 403
vaccine for, 401, 404, 406
hepatitis B
blood supply safety and, 405
burden of, 207
healthcare injection safety and, 405
incidence rates, 401
persons who inject drugs (PWIDs) and, 405
prevention interventions, 209
transmission of, 403
treatment access for, 405
vaccine for, 209, 213, 222, 401, 404, 406
hepatitis C
blood supply safety and, 405
cost-effectiveness of interventions, 407
direct acting antiviral (DAA) medicines for, 401
healthcare injection safety and, 405
HIV/AIDS comorbidity, 198
  incidence rates, 401
  mortality rates, 402
  persons who inject drugs (PWIDs) and, 405, 407
  transmission of, 403–4
  treatment access for, 405
hepatitis D
  incidence rates, 401
  mortality rates, 402
  transmission of, 403
  vaccine for, 401
hepatitis E
  incidence rates, 401
  sanitation improvement interventions, 404
  transmission of, 403
  vaccine for, 401, 404–5
hepatocellular carcinoma (HCC), 45, 48
herpes simplex virus (HSV-1 and HSV-2)
  burden of, 207
  HIV/AIDS comorbidities and, 46
  incidence rates, 7
  male circumcision and, 210
high-density lipoprotein (HDL) cholesterol, 55
high-income countries
  antibiotic use in, 438
  diabetes mellitus incidence rates in, 54
hepatitis in
  cost-effectiveness of interventions, 407
  treatment access, 405
HIV/AIDS in, 138
  cancer comorbidity, 46
  noncommunicable chronic comorbidities, 52
  treatment interventions, 29
  mortality rates in, 2, 2t
  sexually transmitted infections in, 208
  structural interventions, 217
Histoplasma capsulatum, 367
HIV/AIDS, 5–9, 29–232
  90-90-90 targets, 30, 34–35, 39–40
  adherence to treatment, 79–81
    barriers, 79–80
    cost-effectiveness, 81
    decentralized care and, 81
    guidelines, 79
    improvement approaches, 80–81
    measurement of, 79
    peer counseling and, 81
    rationale and coverage, 79
  adolescents, 8
  biology of transmission, 92–93
  cancer comorbidity, 46–50
    anal cancer, 48
    behavioral interventions, 49
cervical cancer, 47
  chemoprevention of, 49
  epidemiology of, 46–47
  hepatocellular carcinoma (HCC), 48
  Kaposi sarcoma (KS), 47
  lung cancer, 48
  lymphoma, 47–48
  pathogenesis of HIV-associated malignancies, 47
  prevention strategies, 48–49
  screening for, 49
  vaccines and, 48–49
  cardiovascular disease comorbidity, 52–54
    ART impact on, 53
    burden of, 52–53
    epidemiology of, 52–53
    factors associated with, 53
  care continuum, 67–90, 68f
    adherence, 79–81
    linking to and engagement with care and treatment services, 75–77
    retention in care, 77–79
    testing services, 67–75, 71–74t
  comorbidities, 45–66
    bacterial vaginosis, 52
    cancer, 46–50
    cardiovascular disease, 52–54
    diabetes mellitus, 54–55
    dyslipidemia, 55–57, 55t
    febrile illness, 368, 368t, 372
    female reproductive health, 50–51
    hepatitis C, 198
    herpes simplex virus, 51
    human papillomavirus (HPV), 51
    malaria, 348
    noncommunicable chronic comorbidities (NCCs), 52–57
    other sexually transmitted infections, 51–52, 115
    pelvic inflammatory disease, 51–52
    sexually transmitted intestinal and enteric infections, 52
    tuberculosis, 234, 239, 245
  DALYs, 33–34
  diabetes mellitus comorbidity, 54–55
    burden of, 54
    epidemiology of, 54
    factors associated with, 54–55
  dyslipidemia comorbidity, 55–57, 55t
    burden of, 55
    epidemiology of, 55
    factors associated with, 55–56
  febrile illness comorbidity, 368, 368t, 372
  female reproductive health comorbidity, 50–51
    family planning and, 50
infertility and, 50–51
intervention packages, 5, 5–6
key populations, 36–37
90-90-90 targets among, 37
defining, 36–37
injecting drug users, 8, 36, 68, 160, 160
men who have sex with men (MSM), 8, 36, 45, 68, 160
sex workers, 8, 36, 68, 159–60, 159
surveillance, 39
linking to and engagement with care and treatment services, 75–77
barriers, 75–76
cost-effectiveness, 76–77
guidelines, 75
measurement of, 75
rationale and coverage, 75
uptake improvement approaches, 76
local epidemics, 157–78
allocative efficiency for interventions, 170–73, 171–73
concentrated epidemics, 158, 159–60, 159–60
cost-effectiveness of interventions, 170–73, 171–73
generalized epidemics, 158, 160–61
geographic targeting and hotspot mapping, 167–70, 168–70
injecting drug users, 8, 160
men who have sex with men (MSM), 8, 160, 160
mixed epidemics, 158, 161
program science approach, 165–67
sex workers, 8, 159–60, 159
tailoring responses to, 161–70, 161–62
transmission dynamics and, 157–61, 158
malaria comorbidity, 348
microepidemics, 35–36, 35–36
surveillance, 39
morbidity rates, 32–33, 32–33
mortality rates, 31–32, 31
mother-to-child transmission (MTCT), 7, 113–36
adherence to treatment and, 122
ART and, 121, 122
assessment of interventions, 124–25
burden of, 114–19, 114r, 116–19
case studies, 129–30, 130
community engagement and, 124
consequences of, 117–18
cost-effectiveness of prevention, 125–29, 126–27, 126
cross-cutting issues for, 123, 123
effectiveness of interventions, 119–21, 120
family planning and, 124
implementation of interventions, 121–24
male partner involvement and, 123–24
noncommunicable and chronic (NCCs), 52–57
cardiovascular disease, 52–54
diabetes mellitus, 54–55
dyslipidemia, 55–57, 55
prevention interventions
barrier methods, 144
categorizing, 138–39
cost-effectiveness of, 137–56
costs of, 146–50, 148–50
defining, 138–39
history of, 137–38
intervention endpoints, 139
male circumcision, 7, 8, 144–45
preexposure prophylaxis (PrEP), 7, 8, 145, 145
prevention cascades, 140, 140, 140, 147
systematic reviews of, 140–43, 141, 142–43
targeting, 150–51, 151
vaccines, 146
vaginal or rectal microbicides, 145–46
provider-initiated testing and counseling (PITC), 68
resource allocation modeling, 179–202
AIDS Epidemic Model (AEM), 180, 181–85, 186, 192, 196–97
AIDS Impact Model (AIM), 186, 187
Avenir Health models, 180, 181–85
behavioral economics and, 198–99
comparison of models, 180–93, 181–85, 198
controversies in, 199–200
Decision Makers’ Program Planning Tool (DMPPT) model, 189–90, 196
Epidemiological Modeling (EMOD), 180, 181–85
external validity of, 198
field experience with, 194–97
Global Health Decisions (GHD) model, 180, 181–85, 186, 192
policy implications, 194–97
Global Resource Needs Estimate (GRNE) model, 187, 196
Goals model, 180, 181–85, 189–89, 189
implementation of, 198
OneHealth Tool, 180, 181–85, 186, 190, 191
Optina HIV model, 180, 181–85, 190–92, 197
policy implications, 194–97
role of, 180, 197
unit cost resources and, 198
What Works Reviews (WWR), 193–94, 193, 195
retention in care, 77–79
barriers, 77–78
cost-effectiveness, 78–79
guidelines, 77
improvement approaches, 78
incentives for, 78–79
measurement of, 77
patient costs and, 78–79
rationale and coverage, 77
treatment supporters, use of, 78
sociocultural barriers to interventions, 7
surveillance
90-90-90 targets, 39–40
challenges in, 37–40
expansion of, 30
key populations, 39
loss to follow-up, 38–39
microepidemics, 39
prevalence and incidence rates, 37–38
syphilis comorbidity, 115
testing services, 67–75, 71–74
treatment as prevention (TasP), 8, 91–112
biological studies, 103–4
clinical studies, 104
cost-effectiveness, 96–102, 98–99
ecological studies, 94
effectiveness of, 93–96, 96f
measurement challenges, 94–95
modeling cost-effectiveness, 100–101
modeling population-level effectiveness, 95–96
pharmacological studies, 103–4
policy implications, 101–3
population-based studies, 94, 104, 104b
public health studies, 104
serodiscordant couples, 93, 102b
targeting of, 164
tuberculosis comorbidity, 234, 239, 245
HIV Infant Tracking System (Kenya), 76
HIV Modelling Consortium, 188
HIV Prevention Trials Network (HPTN), 91
Hodgkin lymphoma, 47, 48
Holmes, King K., 1, 210
Honduras, syphilis in, 203
Hong Kong SAR, China
malaria incidence rates in, 318
tuberculosis in
diagnosis, 249
incidence rates, 240
Horton, Susan, 1
hospitals
antibiotics usage in, 438, 438f, 441
febrile illness treatment in, 371–72
Hotez, P. J., 420
hotspot mapping, 167–70, 168–70m, 169f
HPTN (HIV Prevention Trials Network), 91
HPV. See human papillomavirus
Hsiao, W. C., 235
Humair, S., 97
human African trypanosomiasis (HAT)
cost-effectiveness of interventions, 422
incidence rates, 19, 415
mortality rates, 416
treatment interventions, 18, 423
human herpes virus (HHV-8), 47
human papillomavirus (HPV)
burden of, 7, 207
cervical cancer caused by, 47, 205
HIV/AIDS comorbidities and, 46
male circumcision and, 210
prevention interventions, 209
vaccinations for, 48–49, 209, 213, 222
hygiene, antibiotics usage and, 439–40
hypertension, 54

I
IDUs (injecting drug users). See persons who inject
drugs (PWIDs)
IGRAs (Interferon-Gamma Release Assays), 255
immune reconstitution inflammatory syndrome
(IRIS), 251
immunizations. See vaccines and vaccinations
incidence rates
dengue, 365, 367, 368
febrile illness, 366–68, 368–69
gonorrhea, 203
hepatitis, 401–2, 402f, 402r
hepatitis D, 401
hepatitis E, 401
herpes simplex virus (HSV-1 and HSV-2), 7
human African trypanosomiasis (HAT), 19, 415
malaria, 315
syphilis, 203
trichomoniasis, 203
tuberculosis, 236–37, 237f
visceral leishmaniasis, 19, 415

India
antibiotic resistance in, 433, 434f, 435, 436b
antibiotic use in, 438, 442
febrile illness in, 367
HIV/AIDS in cancer comorbidity, 46
geographic targeting of interventions, 167
incidence rates, 35
linkage to care and treatment, 76, 77
localized intervention programs, 163
prevention interventions, 147, 148
testing services, 70, 75
treatment as prevention (TasP), 95, 97
leprosy in, 415
malaria control and elimination in, 320b, 348
cost-effectiveness of interventions, 331, 334
sexually transmitted infections in, 216
tuberculosis in
community-based care, 266, 268
diagnosis, 250
financing of interventions, 289–90, 290
hospital-based care in, 264
incidence rates, 240
information management system, 275
pharmaceutical supply chain, 272
risk factors, 247
treatment interventions, 255, 282
vaccinations, 255, 256
typhoid burden in, 373
vector control interventions in, 419
visceral leishmaniasis in, 19, 415, 419, 422
Indonesia
febrile illness in, 367
HIV/AIDS in
mixed epidemics, 161, 162f
testing services, 70
malaria control in, 348
resource allocation modeling in, 197
syphilis in, 204
tuberculosis in, 274
typhoid burden in, 373
indoor residual spraying (IRS), 349, 351
influenza, 367, 368, 375, 440
injecting drug users (IDUs). See persons who inject drugs (PWIDs)
Innovative Vector Control Consortium, 321b, 358
insecticide-treated nets (ITNs), 349, 352
Institute for Disease Modeling, 180, 192
Institute for Health Metrics and Evaluation, 31, 32–33, 237
integrase inhibitors, 56
Interferon-Gamma Release Assays (IGRAs), 255
International AIDS Society, 38
International Association of Physicians in AIDS Care, 75, 79
International Epidemiological Databases to Evaluate AIDS, 38
International Health Partnership and Joint Assessment of National Health Strategies and Plans, 190
International Medicines Price Workbook (Health Action), 394
interventions. See treatment interventions; specific interventions
intracytoplasmic sperm injection, 51
intrauterine insemination, 51
Investment Framework, 196
in vitro fertilization, 51
Iran, Islamic Republic of, HIV/AIDS in, 160, 161f
Iraq, malaria elimination in, 315
IRIS (immune reconstitution inflammatory syndrome), 251
IRS (indoor residual spraying), 349, 351
isoniazid, 234, 251
ivermectin, 421
J
Jamison, D. T., 290
Japan
tuberculosis comorbidities in, 245
tuberculosis incidence rates in, 240
tuberculosis intervention program financing in, 280
Japanese encephalitis virus (JEV), 367
Jha, Prabhat, 1
John-Stewart, Grace, 113
Jordan, malaria elimination in, 332
K
Kaestner, R., 217
Kahn, James G., 179
kanamycin, 252, 253
Kaposi sarcoma (KS), 45, 46, 47
Karim, Q. A., 214
Kenya
HIV/AIDS in
concentrated epidemics, 160
geographic targeting of interventions, 168
key populations, 36
linkage to care and treatment, 76
persons who inject drugs (PWIDs), 160
prevention interventions, 148, 149
regional microepidemics, 35–36, 36m
retention in care, 78
testing services, 69, 70
treatment as prevention (TasP), 95, 104b
voluntary male medical circumcision and, 164
malaria vaccine program in, 12
pelvic inflammatory disease in, 52
sexually transmitted infections in, 215, 216
syphilis screening in, 123
tuberculosis in
diagnosis, 262
hospital-based care in, 264
information management system, 275
key populations for HIV/AIDS, 36–37
90-90-90 targets for, 37
defining, 36–37
injecting drug users, 8, 36, 68, 160, 160f
men who have sex with men (MSM), 8, 36, 45, 68, 160, 160f
sex workers, 8, 36, 68, 159–60, 159f
surveillance, 39
Khan, M. J., 333
kidney disease, 247
Kinuthia, John, 113
Kirby Institute, 170
*Klebsiella pneumoniae*, 436b, 440
Knight, Gwen, 233, 287
Korea, Republic of, tuberculosis incidence rates in, 240
Kretzschmar, M. E., 96
Krishnaratne, Shari, 137, 140, 141
Kruk, M. E., 289
Kyrgyz Republic
HIV/AIDS in, 34
malaria elimination in, 315, 318

L
Labrique, A. B., 273
*Lancet* Commission on Investing in Health, 198, 427, 428
Lao People’s Democratic Republic
febrile illness in, 367, 375, 376f
malaria elimination in, 321b
sexually transmitted infections in, 215
Larson, B. A., 129
La Ruche, G., 214
Latin America and Caribbean. See also specific countries
antibiotic use in, 443
behavioral change interventions in, 22
Chagas disease in, 419
HIV/AIDS in
comorbidities, 47
concentrated epidemics, 159, 160
key populations, 36
men who have sex with men (MSM), 160
malaria incidence rates in, 318
sexually transmitted infections in, 214
Latvia, tuberculosis in
community-based care, 266
diagnosis, 249
Laxminarayan, Ramanan, 290, 433
LDL (low-density lipoprotein) cholesterol, 55
Lebanon, malaria elimination in, 332
Leichliter, J. S., 223
leishmaniasis. See cutaneous leishmaniasis;
visceral leishmaniasis
Lengeler, Christian, 347
Lenk, Edeltraud, 411
leprosy
 cost-effectiveness of interventions, 422
 incidence rates, 415
treatment interventions, 18, 423
tuberculosis and, 242, 246
leptospirosis, 366, 367, 368, 369, 375
lesbian, gay, bisexual, and transgender (LGBT) persons,
7, 36, 37. See also men who have sex with men (MSM)
Lesotho, HIV/AIDS in
behavioral change interventions, 164, 165, 165f
generalized epidemics, 161
Levi, J., 34
Levin, Carol, 113, 220, 347
Liberia, tuberculosis vaccinations in, 287
LICs. See low-income countries
linezolid, 253
liposomal amphotericin B (AmBisome), 422
Liu, Jenny, 315
Lives Saved Tool, 186–87
LLINs. See long-lasting insecticide-treated nets
local HIV/AIDS epidemics, 157–78
allocative efficiency for interventions, 170–73, 171–73f, 172r
cost-effectiveness of interventions, 170–73, 171–73f, 172r
generalized epidemics, 158, 160–61
generalized epidemics, 158, 160–61
geographic targeting and hotspot mapping, 167–70, 168–70m, 169f
injecting drug users, 8, 160
men who have sex with men (MSM), 8, 160, 160f
mixed epidemics, 158, 161
program science approach, 165–67
sex workers, 8, 159–60, 159f
tailoring responses to, 161–70, 161–62f, 164–65f, 166m, 167f, 168–70m
transmission dynamics and, 157–61, 158m
Long, E. F., 97
long-lasting insecticide-treated nets (LLINs), 318, 325, 349, 352, 358–59
Lorougnon, F., 214
low-density lipoprotein (LDL) cholesterol, 55
Lubell, Yoel, 365, 375
Luecke, E., 141
lung cancer, 45, 48
Lynamua, R. E., 39
lymphatic filariasis, 2, 415, 418, 423
lymphoma, 47–48
Mabey, David, 113, 210
Madagascar, malaria incidence rates in, 316
Maddali, M. V., 95, 97
Magadi, M. A., 35
Makomva, Kudzai, 315
malaria, 11, 14, 315–64
  burden of, 348, 373, 413, 413r
  comorbidities, 348
  control interventions, 13t, 347–64
    costs and cost-effectiveness of, 350–51
    diagnosis, 350
    effectiveness of, 349–50
  environmental determinants, 351–52
  health system factors, 352–53
  medicine therapies, 353–56, 354–55f
  social determinants, 351–52
  surveillance, 350
  systemic approaches, 351–53
  treatments, 13t, 350
  vector control, 349, 358–59, 358f
elimination and eradication, 315–46
  artemisinin resistance and, 322–24, 323m
  challenges to, 320–21b, 322–24
  defined, 316–17, 317b
  diagnosis and treatment, 327–29
  epidemiological surveillance, 328–29
  financing of, 330–36, 331t, 333–35f, 335–36b
  high-risk populations, 322
  interventions, 324–30, 324–25r
  mass drug administration, 327–28
  milestones and targets, 316, 316r
  program management, 329–30
  progress toward, 318–20, 319m, 320r
  prospects for, 336–37
  research priorities, 337b
  vector control, 325–27
  febrile illness comorbidity, 365
  HIV/AIDS comorbidity, 348
  incidence rates, 315
  medicine therapies, 353–56, 354–55f
    long-term chemoprotection, 355–56
    transmission-blocking medicines, 355
  mortality rates, 316
  surveillance, 11
  vaccines, 11, 329, 356–58, 357f
Malaria Program Efficiency Analysis Tool (MPEAT), 336b
Malaria Vaccine Funders Group, 356
Malaria Vaccine Initiative, 356
Malaria Vaccine Roadmap, 357
Malawi
HIV/AIDS in
  adherence to treatment, 79
  ART interventions, 122
  behavioral change interventions, 164, 165, 165f
  intervention incentives, 143
  linkage to care and treatment, 75, 76
  mother-to-child transmission, 122
  surveillance, 38
  testing services, 68, 69, 70
malaria vaccine program in, 12
sexually transmitted infections in
  partner notification, 215
structural interventions, 217
treatment interventions, 214
Malaysia, malaria control in, 352
Maldives, malaria incidence rates in, 318
male circumcision. See voluntary male medical circumcision (VMMC)
Mali, malaria elimination in, 334
Manhart, L. E., 210
Markov model, 390, 390f, 394
Markowitz, S., 217
Marrazzo, J. M., 144
Marseille, Elliot, 179, 221
Massad, L. S., 51
mass drug administration (MDA), 327–28
Mauritius
  malaria elimination in, 321b, 331, 332
  malaria incidence rates in, 318
Mavedzenge, S. N., 141
Mayaud, Philippe, 203, 210, 220
Mayxay, M., 367
McCarthy, F. D., 333
McNairy, Margaret, 67
MDA (mass drug administration), 327–28
MDGs. See Millennium Development Goals
measles, 2, 22
Médecins Sans Frontières, 102, 274
Medication Event Monitoring System, 79
MEDLINE, 210
melioidosis, 373
MEMA kwa Vijana (intervention program), 216
Ménard, Didier, 315
Menon, Manoj, 45
men who have sex with men (MSM)
  HIV/AIDS among, 138
    adherence to treatment, 80
    concentrated epidemics, 160
    incidence rates, 92
    local epidemics, 8, 160, 160f
    treatment as prevention (TasP), 93, 95
    localized intervention programs for, 163, 167
    preexposure prophylaxis (PrEP) for, 163
resource allocation modeling and, 194
syphilis among, 203–4, 208
voluntary male circumcision and, 145
MERS (Middle East respiratory syndrome), 2
Mexico
HIV/AIDS in, 148
malaria elimination in, 332
Meyer-Rath, G., 100
microbicides
resource allocation modeling and, 194
sexually transmitted infections and, 210
microepidemics, 35–36, 35–36f, 39
Middle East and North Africa. See also specific countries
brucellosis in, 367
HIV/AIDS in
comorbidities, 47
centrated epidemics, 159
key populations, 36
Millennium Development Goals (MDGs), 16, 123, 234, 241, 315, 348, 412
Miller, W. C., 96
Miller-Petrie, Molly, 433
mixed HIV/AIDS epidemics, 158, 161
modeling for resource allocation. See resource allocation modeling
Moldova, tuberculosis in
community-based care, 266
diagnosis, 264
Money, Deborah, 45
morbidity rates. See also comorbidities
dengue, 413, 413f
febrile illness, 397, 397f
HIV/AIDS, 32–33, 32–33f
neglected tropical diseases (NTDs), 413, 413f
sexually transmitted infections, 205
Morocco, malaria elimination in, 315
mortality rates
antiretroviral treatment (ART) and, 208
by country income group, 2, 2t
hepatitis, 16, 402, 403f, 403m
HIV/AIDS, 31–32, 31f
human African trypanosomiasis (HAT), 416
malaria, 316
neglected tropical diseases (NTDs), 412–13, 413f
schistosomiasis, 416
sexually transmitted infections, 205
tuberculosis, 234, 244
visceral leishmaniasis, 416
mother-to-child transmission (MTCT)
hepatitis, 404
HIV/AIDS, 7, 113–36
adherence to treatment and, 122
ART and, 121, 122
assessment of interventions, 124–25
burden of, 114–19, 114r, 116–19m
case studies, 129–30, 130t
community engagement and, 124
consequences of, 117–18
cost-effectiveness of prevention, 125–29, 126–27t, 126f
cross-cutting issues for, 123, 123t
effectiveness of interventions, 119–21, 120t
family planning and, 124
implementation of interventions, 121–24
male partner involvement and, 123–24
resource allocation modeling and, 195
Mozambique
HIV/AIDS in
prevention interventions, 149
retention in care, 78
treatment as prevention (TasP), 102
malaria elimination in, 321b
sexually transmitted infections in, 221
tuberculosis in, 264
MRSA, 433, 434–35
MSM. See men who have sex with men
MTCT. See mother-to-child transmission
mumps, 2
Murdoch, D. R., 367
murine typhus, 367
Murray, Megan, 233
Myanmar
malaria elimination in, 321b, 323
resource allocation modeling in, 197
tuberculosis in, 264
mycetoma, 412
*Mycobacterium avium*, 367
*Mycobacterium bovis*, 242, 255
*Mycobacterium kansasii*, 256
*Mycobacterium leprae*, 242
*Mycobacterium ulcerans*, 414
*Mycoplasma genitalium*, 210
myocardial infarction, 52, 53

N
NAATs (nucleic acid amplification tests), 249
NADCs (non-AIDS defining cancers), 45, 46
Namibia, malaria elimination in, 321b
Naranbhai, V., 248
Nardell, Edward, 233
Natunen, K., 220, 222
NCCs. See noncommunicable chronic comorbidities
Ndowa, F., 220
needle and syringe programs (NSPs), 161, 163, 407
neglected tropical diseases (NTDs), 16–19, 411–48. See also specific diseases
burden of, 19, 412–15, 413–14f
defined, 24n6
global targets for control, elimination, and eradication, 412, 412f
proof of concept for, 415–16, 415f, 416m
intervention packages, 16–18, 18r, 416–20, 417–19t, 417f
cost and cost-effectiveness of, 420–22, 420t
fairness of, 422
individual treatment and care, 419–20
large-scale prevention to entire communities, 18, 416–18
preventive chemotherapy, 18, 416–18, 420, 420t
return on investment for, 425–27, 426m
targeting of, 423–25, 423–24f
morbidity rates, 413, 413r
mortality rates, 412–13, 413r
preventive chemotherapy, 412, 417, 417f, 417f
vector control, 412, 418–19, 418t, 421
Neisseria spp., 366, 433, 435
Nepal
antibiotic use in, 438
antimicrobial resistance in, 439
febrile illness in, 367
malaria elimination in, 332
vector control interventions in, 419
visceral leishmaniasis in, 19, 415

Newby, Gretchen, 315
Newton, Paul N., 365
Next Generation Indoor Residual Spray Project, 321b
NHL (non-Hodgkin lymphoma), 45, 46, 48
nifurtimox-eflornithine combination therapy (NECT), 422
Nigeria
antibiotic resistance in, 433, 434f
ascariasis in, 413
HIV/AIDS in
cancer comorbidity, 46
dyslipidemia comorbidity, 56
geographic targeting of interventions, 167–68, 168–69m, 169f
program science approach, 166–67, 167f
malaria in, 348
cost-effectiveness of interventions, 334
mortality rates, 316
NNRTIs (non-nucleoside reverse transcriptase inhibitors), 55
non-AIDS defining cancers (NADCs), 45, 46
noncommunicable chronic comorbidities (NCCs), 52–57
cardiovascular disease, 52–54
diabetes mellitus, 54–55
dyslipidemia, 55–57, 55r
non-Hodgkin lymphoma (NHL), 45, 46, 48
nonmalarial fever. See febrile illness
non-nucleoside reverse transcriptase inhibitors (NNRTIs), 55
NRTIs (nucleoside reverse transcriptase inhibitors), 47, 56
NSPs (needle and syringe programs), 161, 163, 407
NTDs. See neglected tropical diseases
nucleic acid amplification tests (NAATs), 249
nucleoside reverse transcriptase inhibitors (NRTIs), 47, 56
Nundy, S., 289
Nwankwo, Uzoma, 411

O
Obiero, J., 145
Odeny, T. A., 39
Oman, malaria elimination in, 315, 327
onchocerciasis, 418, 423
OneHealth Tool, 180, 181–85t, 186, 190, 191f
OpenMRS platform, 274
opioid substitution therapy (OST), 161, 163
Optima HIV model, 157, 170, 180, 181–85t, 190–92, 197
oral sex, 207
Orientia tsutsugamushi, 367, 373
Over, M., 100
Owens, D. K., 97
Owens, J. P., 283
Owusu-Edusei, K., Jr., 223

P
Padian, Nancy, 29, 146
Pakistan
antibiotic resistance in, 433, 434f
hepatitis in
cost-effectiveness of interventions, 334
incidence rates, 16
mortality rates, 316
NNRTIs (non-nucleoside reverse transcriptase inhibitors), 55
non-AIDS defining cancers (NADCs), 45, 46
noncommunicable chronic comorbidities (NCCs), 52–57
palliative care, 254
palliative care, 254
palliative care, 254
PaMZ (pretomanid/moxifloxacin/pyrazinamide), 277, 284
Pant, Suraj, 433
Paraguay, malaria elimination in, 315, 318
Partners in Health, 273, 274
PARTNER Study, 93
Peeling, Rosanna W., 113, 130
peer counseling, 81
pelvic inflammatory disease, 46, 51–52
penicillin, 208, 420
Penno, E. C., 375
persons who inject drugs (PWIDs)
  antiretroviral treatment (ART) for, 163
  hepatitis and, 405
HIV/AIDS among, 138
  concentrated epidemics, 160
  interventions targeting, 162–63
  local epidemics, 8, 160
  treatment as prevention (TasP), 95
preexposure prophylaxis (PrEP) for, 163
Peru
HIV/AIDS in
  concentrated epidemics, 160, 160f
  men who have sex with men (MSM), 160
  mother-to-child transmission, 130
sexually transmitted infections in, 216
syphilis in, 129, 130
tuberculosis in
  community-based care, 264
  diagnosis, 262
  information management system, 273, 274, 275
Peterman, T. A., 208
Pettifor, A., 214
phenytoin, 253
Philippines
  leptospirosis in, 373
  malaria elimination in, 331, 334
  resource allocation modeling in, 197
tuberculosis in, 275
Phillips, Allison, 315
PITC (provider-initiated testing and counseling), 68
Plasmodium falciparum, 347–48, 367
Plasmodium knowlesi, 348
Plasmodium malariae, 348
Plasmodium ovale, 348
Plasmodium vivax, 347–48, 367, 386
pneumonia, 19, 366, 378, 433
point-of-care tests (POCTs)
  cost-effectiveness analysis, 378
  for febrile illness, 369, 372, 374, 378
  for influenza, 375
  for malaria, 378
  for sepsis, 375
polio, 2, 22, 336–37
Population Effects of ART to Reduce HIV Transmission (PopART), 104b
Population HIV Impact Assessment (PHIA), 68
Powers, K. A., 96
preexposure prophylaxis (PrEP)
  antiretroviral treatment (ART) and, 93
  cost-effectiveness of, 137, 149
  female reproductive health and, 50
  HIV/AIDS, 7, 8, 145, 145f
  localized intervention programs, 163
  resource allocation modeling and, 194
  sexually transmitted infection prevention via, 209
pregnant women
  febrile illness and, 368, 368t
  hepatitis vaccinations for, 404
  malaria among, 322, 348
  maternal screening for sexually transmitted infections, 222
  syphilis among, 208, 222
tuberculosis among, 253
President’s Emergency Plan for AIDS Relief (PEPFAR), 20, 102, 103, 138, 149, 196
President’s Malaria Initiative, 20, 349
pretomanid/moxifloxacin/pyrazinamide (PaMZ), 277, 284
prevention interventions
  Chagas disease, 421
  chemotherapy, 412, 417, 417f, 417t
dengue, 421
HIV/AIDS
  barrier methods, 144, 210
  categorizing, 138–39
  cost-effectiveness of, 137–56
  costs of, 146–50, 148t, 149–50f
  defining, 138–39
  history of, 137–38
  intervention endpoints, 139
  male circumcision, 7, 8, 144–45
  preexposure prophylaxis (PrEP), 7, 8, 145, 145f
  prevention cascades, 140, 140f, 146, 147f
  systematic reviews of, 140–43, 141f, 142–43t
  targeting, 150–51, 151f
  vaccines, 146
  vaginal or rectal microbicides, 145–46
  sexually transmitted infections, 144, 210
  treatment as prevention (TasP), 8, 91–112
biological studies, 103–4
clinical studies, 104
cost-effectiveness, 96–102, 98–99t
ecological studies, 94
effectiveness of, 93–96, 96f
measurement challenges, 94–95
Index

modeling cost-effectiveness, 100–101
modeling population-level effectiveness, 95–96
pharmacological studies, 103–4
policy implications, 101–3
population-based studies, 94, 104, 104b
public health studies, 104
serodiscordant couples, 93, 102b
targeting of, 164
tuberculosis, 255–61
in hospitals, 259
infection control in congregate settings, 258–61
preventive therapy, 257–58
transmission control, 258–61
vaccinations, 255–56
primaquine, 328, 350, 353
proctitis, 52
proctocolitis, 52
Promoting Maternal-Infant Survival Everywhere (PROMISE), 115, 131n7
prostitution. See sex workers
protease inhibitors, 56
Proteus mirabilis, 366
provider-initiated testing and counseling (PITC), 68
Pseudomonas spp., 366
PubMed, 193
Punjabi, N. H., 367
PWIDs. See persons who inject drugs
pyrazinamide, 251, 253
pyrethroids, 326, 359
Q
Q fever, 366, 367, 368
Quinn, T. C., 92
quinolones, 208, 435
R
rabies, 416
Radhakrishna, S., 256
rapid diagnostic tests (RDTs), 350, 385, 386
RBM. See Roll Back Malaria Partnership
receptivity risk maps, 336b
Reddy, E. A., 366
reproductive health
ART and, 50
family planning and, 50
HIV/AIDS comorbidities and, 45–46, 50–51
infertility and, 50–51
STIs and, 7
República Bolivariana de Venezuela, malaria in, 316
ResistanceMap, 443
resource allocation modeling, 179–202
AIDS Epidemic Model (AEM), 180, 181–85r, 186, 192, 196–97
AIDS Impact Model (AIM), 186, 187
antiretroviral treatment (ART) and, 197, 198
Avenir Health models, 180, 181–85r, 186–90
behavioral economics and, 198–99
comparison of models, 180–93, 181–85r, 198
controversies in, 199–200
Decision Makers’ Program Planning Tool (DMPPT) model, 189–90, 196
Epidemiological Modeling (EMOD), 180, 181–85r, 186, 192
external validity of, 198
field experience with, 194–97
Global Health Decisions (GHD) model, 180, 181–85r, 186, 192–93
Global Resource Needs Estimate (GRNE) model, 187, 196
Goals model, 180, 181–85r, 188–89, 189f
in health system framework, 235f, 236
implementation of, 198
OneHealth Tool, 180, 181–85r, 186, 190, 191f
Optima HIV model, 180, 181–85r, 190–92, 197
policy implications, 194–97
Resource Needs Model (RNM), 180, 181–85r, 187–88, 188f
role of, 180, 197
unit cost resources and, 198
What Works Reviews (WWR), 193–94, 193f, 195f
Resource Needs Model (RNM), 180, 181–85r, 187–88, 188f
Resources for the Awareness of Population Impacts on Development, 186
retention in care, 77–79
Réunion, malaria in, 318
Revell, Paul, 137
rickettsial infections, 367
rifampicin, 234, 251, 253, 272
Rift Valley fever, 367
RNM. See Resource Needs Model
Roberts, M., 235
Roll Back Malaria (RBM) Partnership, 316, 318, 348–49
Romania, tuberculosis in, 266
Ross, D. A., 141
Ross, Ronald, 347
rubella, 2
Rubin, Eric, 233
Russian Federation
antibiotic use in, 438
HIV/AIDS in 90–90–90 targets and, 34
burden of, 116
prevention interventions, 148
tuberculosis in
diagnosis, 263b
hospital-based care in, 264
incidence rates, 237
infection control, 259, 260b
Rutstein, S. E., 221
Rwanda
HIV/AIDS in
  cardiovascular disease comorbidity, 53
  mother-to-child transmission, 124
  prevention interventions, 148
  tuberculosis in
    community-based care, 266
    information management system, 275
S
Sachs, J. D., 333
Sahin-Hodoglugil, N. N., 220
Salmonella enterica, 366, 367, 372, 373, 434, 436b
Salomon, Joshua, 233, 283
Samb, B., 235
Samyshkin, Y., 235
sanitation
  antibiotics usage and, 439–40
  hepatitis treatment interventions, 16, 404
Santos, Michael, 137
São Tomé and Príncipe, malaria elimination in, 332
SARS (severe acute respiratory syndrome), 2
schistosomiasis, 416, 423
scrub typhus, 367, 368, 369
SDGs. See Sustainable Development Goals
SEARCH (Sustainable East Africa Research on Community Health), 104b
Sengupta, A., 289
sepsis, 375
service delivery in health system framework, 235f, 236
sexually transmitted infections (STIs), 5–9, 203–32.
  See also specific infections
adolescents, 8
AIDS mortality and, 208
burden of, 7–8, 204–7
clinician online education for, 9
clustering patterns, 208–9
diagnosis, 206
epidemiology of, 207–8
globalization and, 208–9
gonococcal antimicrobial resistance, 208
key populations, 208
in LMICs, 206–7
in lower middle income countries, 8
morbidty rates, 205
mortality rates, 205
mother-to-child transmission (MTCT), 208
pharmacy treatment of, 9
prevalence of, 203–4, 204f, 204m, 205t, 206f
prevention interventions, 8–9, 9–10r, 209–23
  behavioral change interventions, 210, 219
  case management, 214, 220
  community interventions, 216–17, 221–22
  cost-effectiveness of, 217–22, 218–19t
  effectiveness of interventions, 210–17, 211–13t
  HIV-related benefits of, 222
  HPV vaccines, 210, 213, 220, 222
  income inequality and, 222–23
  male circumcision, 210, 219–20
  mass treatment, 216, 221
  maternal screening, 222
  microbicides, 213–14, 220
  partner notification and management, 214–15, 221
  periodic presumptive treatment, 215–16, 221
  research agenda, 223
  structural interventions, 216–17, 221–22
  targeted interventions, 215–16, 221
  sexual behaviors and, 8, 207
  social determinants, 208–9
sex workers
  HIV/AIDS among, 138
  adherence to treatment, 81
  concentrated epidemics, 159, 159f
  local epidemics, 8, 159–60, 159f
  localized intervention programs, 163
  treatment as prevention (TasP), 95
  localized intervention programs for, 167
Sharma, N. P., 367
Shaw, A. V., 366
Shigella spp., 366
Shretta, Rima, 315, 347
Sierra Leone, tuberculosis in, 287
silicosis, 247
Singapore
  malaria in
    cost-effectiveness of interventions, 332
    incidence rates, 318
    syphilis in, 203
    tuberculosis in
diagnosis, 249
    incidence rates, 240
Situational Analysis of Sexual Health, 209
smallpox, 336–37, 338n5
SMART (Strategies for Management of Antiretroviral Therapy), 53
snakebites, 16
sociocultural barriers to interventions, 7
soil-transmitted helminthiasis (STH), 416, 421
Solomon Islands, malaria elimination in, 321b
South Africa
  antibiotic use in, 438, 442
antimicrobial resistance in, 439, 440, 440b
bacterial vaginosis in, 52
HIV/AIDS in
  adherence to treatment, 80, 81
  behavioral change interventions, 164
  burden of, 115
  cancer comorbidity, 46
  cardiovascular disease comorbidity, 53
  comorbidities, 46
  dyslipidemia comorbidity, 55
  generalized epidemics, 160, 161f
  incidence rates, 35
  linkage to care and treatment, 76, 77
  mother-to-child transmission, 125, 129–30
  prevention interventions, 148
  retention in care, 78
  testing services, 70
  treatment as prevention (TasP), 94, 95, 96, 97, 101, 104b, 164
  voluntary male medical circumcision and, 164
malaria elimination in, 321b, 331
sexually transmitted infections in
  community-based interventions, 217
  microbicide interventions, 214
  targeting of interventions, 215
tuberculosis in
  community-based care, 266
  comorbidities, 245
  costs of treatment, 285, 287
  diagnosis, 250, 262, 263
  hospital-based care in, 264
  incidence rates, 236
  infection control, 259, 260, 261
  preventive therapy, 257–58
  research and development, 283
  treatment interventions, 253, 282
  vaccinations, 256
  voluntary male circumcision in, 144
South Asia
  antibiotic resistance in, 434
  febrile illness in, 367–68
  hepatitis in
    incidence rates, 16
    mortality rates, 401
  HIV/AIDS in
    comorbidities, 47
    morbidity rates, 33
South-East Asia
  febrile illness in, 367–68
  hepatitis in, 404
  malaria control in, 348
  sexually transmitted infections in, 203
  tuberculosis in, 237
Spectrum (modeling software), 186, 187, 200n2
sperm washing, 51
Sri Lanka
  febrile illness in, 386
  malaria in, 315, 317, 318, 330b, 338n1
  cost-effectiveness of interventions, 331, 332
  incidence rates, 318
  vector control, 327
Standards for Reporting of Diagnostic Accuracy, 372
Staphylococcus aureus, 367, 433, 436b, 440
Steen, R., 215
stigma
  HIV/AIDS, 36, 37, 69, 79
  leishmaniasis, 422
  sexually transmitted infections in, 206
  of visceral leishmaniasis, 415
STIs. See sexually transmitted infections
Stop TB Initiative, 240
Stop TB Partnership, 240, 241, 291
Stover, John, 179, 188
Strategies for Management of Antiretroviral Therapy (SMART), 53
Streptococcus pneumoniae, 367, 372
streptomycin, 253
Sub-Saharan Africa. See also specific countries
  antibiotic resistance in, 434
  brucellosis in, 367
  cervical cancer in, 47
  febrile illness in, 373, 385
  HIV/AIDS in, 5, 29, 30
    90-90-90 targets and, 34
    adherence to treatment, 79, 80
    ART and, 35
    burden of, 115
    comorbidities, 47
    concentrated epidemics, 159, 160
    cost-effectiveness of interventions, 67
    diabetes mellitus comorbidity, 54
    dyslipidemia comorbidity, 56
    geographic targeting of interventions, 167–68
    key populations, 36
    linkage to care and treatment, 75, 76
    local epidemics, 158, 158m
    mortality rates, 31, 31f
    mother-to-child transmission, 126, 130
    noncommunicable chronic comorbidities, 57
    persons who inject drugs (PWIDs), 160
    prevention interventions, 148
    regional microepidemics, 35
    retention in care, 77, 78
    surveillance, 38
    testing services, 69, 70
    treatment as prevention (TasP), 95, 97
Kaposi sarcoma (KS) incidence in, 47
malaria control and elimination in, 11, 316, 321b, 348, 353
treatment interventions, 350
vector control, 325, 349
mother-to-child transmission, 129, 130
neglected tropical diseases in
burden of, 413
cost-effectiveness of interventions, 421
resource allocation modeling in, 195, 196
sexually transmitted infections in, 203
partner notification, 221
structural interventions, 217
treatment case management, 220
syphilis in, 122
tuberculosis in
burden of, 237
community-based care, 268
diagnosis, 262, 263
incidence rates, 237
treatment interventions, 282
voluntary male circumcision in, 51, 144
Sudan, visceral leishmaniasis in, 415
sulfadoxine/pyrimethamine (SP), 385
Supervie, V., 93
surveillance
antibiotics usage, 442–43
febrile illness, 375
HIV/AIDS
90-90-90 targets, 39–40
challenges in, 37–40
expansion of, 30
key populations, 39
loss to follow-up, 38–39
microepidemics, 39
prevalence and incidence rates, 37–38
malaria, 11, 328–29, 350
Sustainable Development Goals (SDGs), 11, 24n4, 234, 241, 412, 425, 427
Sutherland, I., 256
Svandova, E., 256
Swanson, R. C., 235
Swaziland
HIV/AIDS
allocative efficiency for interventions, 171–73, 172f, 172r
centered epidemics, 159
generalized epidemics, 161
treatment as prevention (TasP), 164
malaria elimination in, 321b
cost-effectiveness of interventions, 332
surveillance, 328–29
tuberculosis incidence rates in, 240
Sweat, M., 221
syphilis
burden of, 7, 207
HIV comorbidity, 115
incidence rates, 203
mother-to-child transmission (MTCT), 113, 208
burden of, 114–19, 114t, 116–19m
consequences of, 118–19
cost-effectiveness of prevention, 125–29, 126f, 128–29t
cross-cutting issues for, 123, 123t
effectiveness of interventions, 121
penicillin treatment and, 121
screening during pregnancy, 222
pediatric burden of, 116–17, 117m
transmission of, 114–15
Syrian Arab Republic, malaria elimination in, 315, 332
T
Taaffe, Jessica, 157
tafenoquine, 327
Taiwan, China
HIV/AIDS in, 94
malaria elimination in, 318, 338n3
tuberculosis in, 255
Tajikistan, malaria elimination in, 321b
Tanner, Marcel, 347
Tanser, F., 94
Tanzania
febrile illness analytical model, 386–97, 391–97t.
See also febrile illness
HIV/AIDS in
behavioral change interventions, 164, 165, 165f
dyslipidemia comorbidity, 55, 56
testing services, 69, 70
malaria elimination in, 317
sexually transmitted infections in
community-based interventions, 216
treatment interventions, 214
syphilis in, 117, 121, 122, 129, 208
tuberculosis in
community-based care, 266
hospital-based care in, 264
research and development, 283
Tatarsky, Allison, 315
TB Alliance, 240, 278
TB Supranational Reference Laboratory Network, 249
Tediosi, Fabrizio, 347
telemedicine to support health workers, 274
Terris-Prestholt, F., 129, 220
testing services for HIV/AIDS, 67–75, 71–74t
barriers, 69
community-based testing, 70, 75
cost-effectiveness, 70–75, 71–74
early infant diagnosis, 75
guidelines, 68
measurement of, 68–69
rationale and coverage, 67–68
uptake improvement approaches, 69–70
voluntary counseling and testing, 70
tetanus, 22
tetracycline, 208
Thailand
HIV/AIDS in
concentrated epidemics, 160
diabetes mellitus comorbidity, 54
dyslipidemia comorbidity, 55
geographic targeting of interventions, 168
men who have sex with men (MSM), 160
mother-to-child transmission, 127
sex workers and, 138
malaria elimination in, 321
sexually transmitted infections in, 210
Tuberculosis in, 250–55, 252t
vaccine development and, 23
visceral leishmaniasis, 18, 423
Treponema pallidum, 216
trichomoniasis, 7, 145, 203, 207, 210
triglycerides, 55
Trypanosoma cruzi, 414
tuberculosis, 10–11, 233–313
burden of, 237–42, 238–39t
community-based care, 264–69, 266f, 267t
efficiency and effectiveness, 265–66, 267t
human resource challenges, 267
private sector challenges, 267–68
recommendations, 292
targeting, 268–69
comorbidities, 234, 239, 245–46
cost-effectiveness of interventions, 281–89, 285–86t, 288f
diagnosis, 248–50, 249b, 261–64, 263b, 292
DOTS strategy, 291
financing for programs, 280–81, 280–81f, 289–90, 290r
global response, 240, 240b, 241f, 242b
historical trends, 236–37
HIV/AIDS comorbidity, 234, 239, 245
incidence rates, 236–37, 237f
information management and, 272–75
mortality rates, 234, 244
prevention interventions, 255–61
in congregate settings, 258–61
in hospitals, 259
preventive therapy, 257–58
transmission control, 258–61
vaccinations, 255–56
research and development, 275–80
medication optimization, 276–77
recommendations, 293
treatment interventions, 277–78
vaccines, 278–79
risk factors, 246–48, 246–47f
screening, 248–50, 249b
SMS reminders to improve adherence, 274–75
stages and intervention points, 242–44, 243f
strains of, 244–45
supply chains and, 269–72, 270–71f
telemedicine to support health workers, 274
transmission control, 258–61
air disinfection, 260
cost-effectiveness of, 260
in hospitals, 259
in households, 261
masks and respirators, 260–61
measuring effectiveness of, 259–60
principles of, 259
treatment interventions, 12f, 234, 250–55, 252r
adherence, 274–75
antidiabetic treatment, 254
ART, 253–54
cascade of care, 254–55
DOTS strategy, 234, 240–41, 240b, 254, 291–92
drug toxicities and interactions, 253
first-line treatment of drug-susceptible TB, 251
palliative care, 254
recommendations, 292
second-line treatment of MDR TB, 251–53
surgery, 254
vaccinations, 233, 243
universal public financing for treatment of, 289–90, 290t

Tuberculosis Impact Model and Estimates, 186
Turkey, malaria elimination in, 315
Turkmenistan, malaria elimination in, 315, 329b
typhoid, 367, 368, 369, 373
Typhoid Fever Surveillance in Africa Program, 434

U

Uganda
HIV/AIDS in
adherence to treatment, 80, 81
cancer comorbidity, 46
diabetes mellitus comorbidity, 54
incidence rates, 138
linkage to care and treatment, 76
mother-to-child transmission, 130
prevention interventions, 148
retention in care, 78
surveillance, 38
testing services, 69, 70, 75
treatment as prevention (TasP), 95, 100, 104b
voluntary male medical circumcision
malaria in
cost-effectiveness of interventions, 333
incidence rates, 316
neglected tropical diseases in, 422
sexually transmitted infections in
mass treatment interventions, 216
partner notification, 215
treatment interventions, 214
syphilis in, 130
tuberculosis in
hospital-based care in, 264
treatment interventions, 282
voluntary male circumcision in, 144
Ukraine
HIV/AIDS in, 160
tuberculosis in, 264
Ukwaja, K. N., 285
UNAIDS. See United Nations Programme on HIV/AIDS
United Arab Emirates, malaria elimination in, 315
United Kingdom
antimicrobial resistance in, 439, 443
sexually transmitted infections in, 207
tuberculosis in
financing intervention programs, 280
incidence rates, 236
research and development, 279
vaccinations, 255
United Nations Office on Drugs and Crime, 163
United Nations Programme on HIV/AIDS (UNAIDS), 5, 30, 31, 32, 67, 69, 163
on mother-to-child transmission of HIV, 113, 125
Reference Group on Estimates, Modelling and Projections, 39
resource allocation modeling and, 179, 187
surveillance and, 38
United States
antibiotic use in, 438, 441
antimicrobial resistance in, 439
cardiometabolic disease in, 52
diabetes mellitus in, 54
dyslipidemia in, 55, 56
hepatitis treatment in, 407
HIV/AIDS in
diabetes mellitus comorbidity, 54
dyslipidemia comorbidity, 56
female reproductive health and, 51
key populations, 36–37
linkage to care and treatment, 76
localized intervention programs, 163
men who have sex with men (MSM), 163
regional microepidemics, 36, 37m
treatment as prevention (TasP), 95, 97
HPV vaccinations in, 49
infertility treatment in, 51
influenza vaccinations in, 440
malaria control and elimination in, 317, 352
vector control, 326
sexually transmitted infections in, 203, 208
behavioral change interventions, 207
burden of, 206–7
microbicide interventions, 214
partner notification, 215
structural interventions, 217
tuberculosis in
incidence rates, 236
infection control, 259
preventive therapy, 257, 258
research and development, 276
universal public finance (UPF) for tuberculosis treatment, 289–90
University of California, San Francisco, 180, 192, 199
U.S. Agency for International Development (USAID), 187, 196
Uzbekistan, malaria elimination in, 315, 318
V
vaccines and vaccinations
antibiotics and antimicrobial resistance, 440–41
bacille Calmette–Guérin (BCG) vaccine, 233, 243, 255–56, 278, 279
cost-effectiveness of, 20
hepatitis, 16, 49, 401, 404–5, 404f, 406
hepatitis A, 401, 404, 406
hepatitis B, 209, 213, 222, 401, 404, 406
hepatitis D, 401
hepatitis E, 401, 404–5
HIV/AIDS, 48–49
human papillomavirus (HPV), 48–49, 209, 213, 222
influenza, 440
malaria, 11, 329, 356–58, 357f
resource allocation modeling and, 194
tuberculosis, 233, 243, 255–56
Vanuatu, malaria elimination in, 321b, 332
Vassall, Anna, 233, 281
vector control
dengue, 419, 424, 427
malaria, 325–27, 349, 358–59, 358f
neglected tropical diseases (NTDs), 412, 418–19, 418r, 421
Venezuela. See República Bolivariana de Venezuela
Verguet, S., 290
Vickerman, P., 220, 222
Vietnam
antibiotic use in, 438
antimicrobial resistance in, 439
dengue in, 414–15
HIV/AIDS in
90-90-90 targets and, 34
localized intervention programs, 165, 166m
treatment as prevention (TasP), 95, 97
malaria elimination in, 321b, 323
sexually transmitted infections in, 217
syphilis in, 203
tuberculosis in
community-based care, 268
hospital-based care in, 264
viral hepatitis. See hepatitis
visceral leishmaniasis
cost-effectiveness of interventions, 374, 422
incidence rates, 19, 415
mortality rates, 416
treatment interventions, 18, 423
Volchenkov, Grigory, 233
voluntary male medical circumcision (VMMC)
HIV/AIDS interventions and, 7, 97, 144–45, 164
resource allocation modeling and, 189–90, 194, 196, 198
sexually transmitted infection prevention, 209, 210
vulvar intraepithelial neoplasia, 51

**W**

Wagner, B. G., 95
Walensky, R. P., 97
Walker, D., 146
warfarin, 253
Wasserheit, J. N., 210
Weller, S. C., 144
Wells, Tim, 347
West Africa. See also specific countries
hepatitis in
incidence rates, 16
mortality rates, 401
prevalence, 401
HIV/AIDS in, 161
Wetmore, C. M., 210
What Works Reviews (WWR), 193–94, 193f, 195f
White, Richard, 233
WHO. See World Health Organization
Wiedeman, Danielle, 29
Wiktor, Stefan Z., 401
Wilson, David, 95, 157
Wilson, Douglas, 233
Wolf, H., 333
women. See also sex workers
family planning and, 50
febrile illness and, 368, 368t
hepatitis vaccinations for, 404
infertility and, 50–51
malaria among, 322, 348
maternal screening for sexually transmitted infections, 222
reproductive health, 45–46, 50–51
syphilis among, 208, 222
tuberculosis among, 253
World Bank, 170, 180, 190
World Health Assembly, 16, 24n6, 315, 318, 349, 412, 439
World Health Organization (WHO)
on cervical cancer screening, 49
Clinical Staging and Disease Classification System, 24n1
on febrile illness, 366, 385, 398
Global Health Estimates, 31
Guidelines Group on Couples HIV Testing and Counseling, 102, 102b
on hepatitis, 407
on hepatitis vaccinations, 49
HIV prevention cascade, 140
on HPV vaccinations, 48–49
Integrated Management of Adolescent and Adult Illness (IMAI), 371, 375
International Health Regulations, 1
on malaria, 11–12, 315, 349
malaria treatment guidelines, 371
on mother-to-child transmission of HIV, 113
on neglected tropical diseases, 16
NTD Roadmap, 412, 416, 418, 423, 427
resource allocation modeling and, 190, 199
on sexually transmitted infections, burden of, 7
on syphilis incidence rates, 117, 122
on treatment as prevention (TasP), 164
on tuberculosis, 10, 233, 235, 242b, 269b, 280
vector management strategy, 418
World Organisation for Animal Health, 440b
Wu, Y., 333
WWR (What Works Reviews), 193–94, 193f, 195f

**X**

Xpert MTB/RIF test, 250, 261–62, 281–82, 292

**Y**

Yadav, Prashant, 233
yaws
cost-effectiveness of interventions, 422
treatment interventions, 2, 18, 420, 423, 427
Ying, R., 100
Yuen, C. M., 263

**Z**

Zambia
HIV/AIDS in
adherence to treatment, 79, 80
linkage to care and treatment, 75
mother-to-child transmission, 130
prevention interventions, 148
surveillance, 38
testing services, 68
treatment as prevention (TasP), 95, 97, 101, 104b
malaria control and elimination in, 321b, 352
syphilis in, 129, 130
tuberculosis in
community-based care, 266
diagnosis, 261, 263
Zanzibar, malaria elimination in
cost-effectiveness of interventions, 332
financing of interventions, 335b
Zika virus, 2, 8, 18, 22, 421
Zimbabwe
   HIV/AIDS in
      adherence to treatment, 79, 80
      cardiovascular disease comorbidity, 53
      incidence rates, 35, 35f, 138
      linkage to care and treatment, 75
prevention interventions, 146, 147f, 149
retention in care, 77
surveillance, 38
testing services, 68
malaria elimination in, 321b
sexually transmitted infections in, 214
tuberculosis in, 272
Zwerling, A., 284
The World Bank Group is committed to reducing its environmental footprint. In support of this commitment, we leverage electronic publishing options and print-on-demand technology, which is located in regional hubs worldwide. Together, these initiatives enable print runs to be lowered and shipping distances decreased, resulting in reduced paper consumption, chemical use, greenhouse gas emissions, and waste.

We follow the recommended standards for paper use set by the Green Press Initiative. The majority of our books are printed on Forest Stewardship Council (FSC)–certified paper, with nearly all containing 50–100 percent recycled content. The recycled fiber in our book paper is either unbleached or bleached using totally chlorine-free (TCF), processed chlorine-free (PCF), or enhanced elemental chlorine-free (EECF) processes.

More information about the Bank’s environmental philosophy can be found at http://www.worldbank.org/corporateresponsibility.